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Abstract 
African trypanosomiasis is a disease caused by protozoan parasites i.e. Trypanosoma spp. in 
livestock and humans and affects 37 sub-Saharan countries.  Animal African trypanosomiasis 
(AAT) is known as nagana and African human trypanosomiasis (HAT) as sleeping sickness. 
Trypanosoma congolense, T. vivax and T. brucei brucei cause AAT which is an economic 
burden and hampers agricultural development in Africa. The parasite escapes the host’s 
immune response by switching the genes coding for the variable surface glycoproteins, 
resulting in new variable antigen types. This has made it unlikely to develop a vaccine against 
the disease and therefore many studies now focus on non-variant trypanosome antigens as 
potential diagnostic and drug targets.   
Trypanosomal cysteine proteases, such as the cathepsins B and L, have been identified and 
validated as potential diagnostic targets. They are expressed throughout the parasite life cycle 
and are essential for the survival of the parasite. The mammalian host produces an antibody 
response against trypanosomal cysteine proteases which do not affect the survival of the 
parasite, however, the antibodies are believed to play a role in trypanotolerance by neutralising 
the effects of the enzyme.  
Antigen-based ELISA is a good tool for accurate diagnosis of AAT, but also relies on good 
antibodies. The overall aim of this study was to produce antibodies against the cathepsin-L-
like protease of T. b. brucei (TbbCATL) which can be used for specific diagnosis of T. b. brucei 
infections. This included polyclonal antibodies as well as single chain variable fragments 
(scFvs) using phage display. The protease, TbbCATL, was recombinantly expressed in E. coli 
for the first time as a 61 kDa protease (including the GST tag) using the pGEX-4T expression 
vector. The homologues from T. congolense (TcoCATL) (29 kDa) and T. vivax (TviCATL) (28 
kDa and 32 kDa) were also recombinantly expressed using the P. pastoris yeast expression 
system and were shown to hydrolyse the Z-Phe-Arg-AMC substrate and to be inhibited by E-
64. Antibodies against whole TbbCATL were produced in chickens and together with anti-
TcoCATL peptide antibodies and anti-TviCATL antibodies, were evaluated in a western blot 
to determine possible cross-reactivity. Whereas the anti-TbbCATL antibodies were specific for 
TbbCATL, the anti-TcoCATL peptide and anti-TviCATL antibodies cross-reacted with 
TbbCATL. The production of scFvs was optimised using TviCATL as the panning antigen 
against the Nkuku® phage display library.  The TviCATL-specific phages were enriched after 
the fourth round of panning and a total of seven clones gave high signals when analysed by 
monospecific ELISA. Future work will include recombinant expression and purification of the 
selected TviCATL-specific scFvs for testing in diagnostic assays as well as panning with the 
TbbCATL antigen. This study laid the groundwork for evaluating TbbCATL as a diagnostic 
target for AAT   
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Chapter 1 
Literature Review 
1.1 Introduction 
African trypanosomiasis (AT) is a disease caused by flagellated protozoan parasites i.e. 
Trypanosoma spp. in livestock and humans and affects 37 sub-Saharan countries. African 
animal trypanosomiasis (AAT) is known as nagana and human African trypanosomiasis (HAT) 
as sleeping sickness. There are approximately 30 species of tsetse flies (Glossina spp.) 
inhabiting the humid regions of Africa which are responsible for transmitting both HAT and 
ATT causing trypanosomes (Muhanguzi et al., 2017). The prevalence of the trypanosome 
parasite correlates with the distribution of the tsetse fly vector which covers 10 million km2 land 
in sub-Saharan Africa (Fig. 1.1) (Yaro et al., 2016). The tsetse fly is found between 14̊ N and 
29̊ S of the equator where the environment is suitable for their survival and reproduction 
(Mitchell, 2018).  
Sleeping sickness is caused by two Trypanosoma brucei sub-species namely Trypanosoma 
brucei gambiense which causes the chronic form in west and central Africa, and T. b. 
rhodesiense which causes the acute form in east and southern Africa (Brun et al., 2010). This 
disease occurs in two clinical stages. The first stage is known as the haemo-lymphatic stage 
where the parasites invade the lymphatic system and bloodstream. After some time, the 
parasites cross the blood-brain barrier and invade the central nervous system, this is the 
second clinical stage known as the meningo-encephalytic stage (Brun et al., 2010). Nagana, 
on the other hand, is caused by T. congolense, T. vivax and to a lesser extent T. b. brucei. 
These species invade the bloodstream causing anaemia (Noyes et al., 2009). Whereas other 
species develop in the vector midgut, T. vivax develops in the mouthparts of the insect vector 
where it undergoes a complete life cycle. Due to this, T. vivax can be mechanically transmitted 
by other haematophagous flies such as horseflies (Tabanus spp.) and stable flies (Stomoxys 
spp.)  and is consequently also found in parts of Asia and South America (Giordani et al., 
2016; Radwanska et al., 2018).  
Another important trypanosoma species is T. cruzi which causes American trypanosomiasis, 
known as Chagas diseases in humans. There are more than 100 blood sucking Triatominae 
species that can serve as vectors for this parasite. While transmission of T. b. gambiense and 
T. b. rhodesiense occurs via the saliva of vectors during a blood meal, T. cruzi is deposited 
with parasite-laden faeces of the vector during a blood meal. Infected individuals develop 
cardiac and gastrointestinal problems associated with chronic symptoms of Chagas disease 
(Kowalska et al., 2011). 
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The Food and Agriculture Organisation (FAO) of the United Nations declared trypanosomiasis 
a major threat to the economy and agricultural production on the African continent (Mattioli et 
al., 2004). At least three million cattle die annually, affecting the livelihood of local farmers who 
depend on cattle as a source of income, meat, milk and manure (Giordani et al., 2016). To 
date, there is no conventional vaccine for trypanosomiasis due to the continuously changing 
surface coat of the parasites, hence this disease is controlled mainly by trypanocidal drugs. 
The effect of these trypanocides, however, is limited by several factors, the major factor being 
the emergence of drug-resistant strains. Due to this, many research studies have been aimed 
at understanding drug-susceptible strains for appropriate drug prescription and administration, 
as well as host-parasite interactions to provide the understanding of the disease and drug 
resistance mechanisms (Sutcliffe et al., 2014). Furthermore, the FAO has implemented quality 
control checks to improve the quality of veterinary drugs (Giordani et al., 2016).  
 
                                   
Figure 1.1: Distribution map of tsetse flies and cattle in Africa. Accessed from 
http://www.irinnews.org/news/2009/05/12/tsetse-fly-costs-agriculture-billions-every-year. 
 
1.2 Classification of trypanosomes 
Trypanosomes belong to the genus Trypanosoma, family Trypanosomatidae, order 
Kinetoplastida (due to the presence of a kinetoplast) and class Sacomastigophora (Hoare, 
1972). The genus is further divided into two groups namely stercoraria and salivaria (Fig. 1.2). 
In the stercoraria group, the parasite develops in the intestine of the invertebrate vector and 
transmission to the vertebrate occurs via faeces (e.g. T. cruzi which is responsible for Chagas 
disease). The parasites of the salivaria group develop in the gut of the vertebrate host and 
move towards the salivary gland where they develop into the form that is infectious to the 
vertebrate host. Included in this group are subgenera Nannomonas, Duttonella, Trypanozoon 
and Pyconomonas. Subspecies T. congolense and T. vivax belong to subgenera 
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Nannomonas and Duttanella respectively and are pathogenic to livestock (Table1.1). 
Subgenera Trypanozoon includes T. brucei with three sub-species; T. b. brucei (infects 
livestock but is not pathogenic), T. b. rhodesiense and T. b. gambiense which cause sleeping 
sickness in humans (Majiva et al., 1986). The Trypanozoon species T. equiperdum and T. 
evansi, are transmitted by biting insects and infect camels and horses in northern Africa and 
parts of Asia (Table 1.1) (Radwanska et al., 2018).  
1.3 Morphology and life cycle of trypanosomes 
The trypanosome is a unicellular organism which varies from 8 to 50 µm in size. This parasite 
is unique among the flagellated protozoans in that the flagellum is attached to the cell body 
(Fig. 1.3) producing waves from the ends of the body, resulting in a wriggling movement 
observed in culture media or blood smears (Schuster et al., 2017). The parasite is 
characterised by a kinetoplast, which is a compact disc of mitochondrial DNA known as 
kinetoplast DNA (kDNA). The kDNA contains two types of topologically interlocked DNA 
circles i.e. maxi circles and mini circles. Maxi circles (22 kb) are found in dozens per cell and 
contain conserved sequences that code for RNA and a few mitochondrial proteins. To form 
functional mRNA, the maxi circles require high fidelity editing which is controlled by a guide 
mRNA encoded in the high copy number mini circles (1 kb) which have variable sequences 
(Liu et al., 2005).  
The position of the kinetoplast changes during the different life cycle stages. During the 
trypomastigote stage (in the host) it is located at the posterior end of the organism and during 
the epimastigotes stage (in the insect vector) it is located at the anterior end. The 
mitochondrion extends towards the anterior end and does not contain cristae during the 
bloodstream form therefore, mitochondrial respiration does not occur. In this stage, energy 
generation occurs in the glycosomes via glycolytic reactions. On the other hand, the 
mitochondrion is highly active during the procyclic form as energy generation is dependent on 
the electron transport chain in the absence of blood glucose (Matthews, 2005).  
The nucleus contains the DNA responsible for the synthesis of enzymes and proteins of the 
cell. Beneath the cell membrane are tightly packed microtubules which limit access into the 
cell, thus the flagellar pocket (specialised invagination) is the only site for endocytosis and 
exocytosis  (Parsons, 2004; Matthews, 2005). Material internalised for nutritional or immune 
invasion purposes enter the parasite by endocytosis and are transported via endosome 
compartments to the lysosomes where they are proteolytically degraded (O'Brien et al., 2008).
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  Species 
   Subspecies 
Salivaria Stercoraria 
Subgenus 
Group 
Trypanosomatidae 
Family 
Genus 
Trypanosoma Crithidia Leishmania 
Protozoa 
Kinetoplastida 
Phylum 
Order 
Nannomonas Pycnomonas Herpetosoma Schizotrypanum Duttonella Megatrypanum Trypanozoon 
Trypanosoma  evansi 
T. equiperdum 
T. brucei: 
  T. b. brucei 
  T. b. gambiensis 
  T. b. rhodesiense 
Trypanosoma godfreyi 
T. simiae 
T. congolense 
Trypanosoma suis Trypanosoma vivax 
  T. v. viennei 
T. uniforme 
Trypanosoma lewisi 
T.musculi 
Trypanosoma theileri Trypanosoma cruzi 
  T.c.marinkellei 
T. rangeli 
Figure 1. 2 
 
 
    
 
 
 
  
 
 
 
 
 
 
                : Classification of trypanosomes (Stevens and Gibson, 1999; Stevens and Brisse, 2004; Baral, 2010). This review focuses on the underlined 
species.
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Table 1.1: Animal infective trypanosoma species and geographic areas where they 
occur (Giordani et al., 2016; Cooper et al., 2017) 
Trypanosoma spp. Affected animals Geographic distribution 
T. congolense Cattle, sheep, goats, pigs, 
horses, dogs 
Tsetse regions of Africa 
T. vivax Cattle, sheep, goats, horses, 
camels 
Africa, central and south 
America, west Indies 
T. brucei brucei Cattle, dogs, camels, horses  Tsetse regions of Africa 
T. simiae Sheep, goats, camels, horses, 
pigs 
Tsetse regions of Africa 
T. equiperdum Horses, donkeys, mules Africa, Asia, middle east 
T. evansi Cattle, horses, water buffalo, 
dogs 
Asia, Africa, South and Central 
America 
 
              
Figure 1.3: Diagrammatic representation of the morphology of a trypanosome, T. brucei showing 
its major organelles. Accessed from http://agsavet.blogspot.com/2011/12/trypanosomiasis.html 
 
Trypanosomes initially multiply within the midgut of the insect vector before migrating to the 
mouthparts as the mammalian infective metacyclic form (Fig. 1.4; stages 1 to 5). The 
metacyclic parasite develops in the proboscis in the case of Nannomonas and the salivary 
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glands in the case of Trypanozoon. During a blood meal, the insect vector injects the 
metacyclic parasites into the skin of the mammalian host from where they enter the blood via 
the lymphatic system. In the early stages, the parasites are long, slender and divide rapidly by 
binary fusion causing an increase in parasitaemia. During peaks of parasitaemia, the stumpy 
form is established, does not divide and is pre-adapted for survival in the vector after it is taken 
up in a blood meal. In the vector midgut, the stumpy form differentiates into the procyclic form. 
The parasite moves through the midgut to the proventriculus and differentiate into 
epimastigote and finally the metacyclic form in the salivary glands (Fig. 1.4) (Sunter and Gull, 
2016). 
                      
Figure 1.4: Schematic representation of the life cycle of T. brucei in the tsetse and mammalian 
hosts. (Silvester et al., 2017).  
 
1.4 Antigenic variation of trypanosomes 
A feature unique to trypanosomes is the replaceable cover coat made up of variable surface 
glycoprotein (VSG) which specifies the variable antigen type (VAT) (Ponte-Sucre, 2016). 
There are more than 107 VSG genes encoded in the parasite’s genomic repertoire. 
Transcription of the VSG mRNA occurs from one of many telomeric bloodstream form sites 
while the other sites are silenced, therefore only one gene at a time is expressed on the 
surface of the parasite at any time (Glover et al., 2013). During mammalian infection, the VSG 
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generates a host immune response which eliminates the majority of the parasites, and only a 
few slender cells survive by switching the expressed VSG, resulting in a new wave of 
parasitaemia. The stumpy cells on the other hand, do not switch their VSG but enter cell cycle 
arrest thus cannot generate new variants. These cells however, can rapidly eliminate anti-
VSG antibodies by endocytosis, causing a delay in cell lysis. Due to this, their survival is 
prolonged which increases the chances of transmission (Silvester et al., 2017). The VSG 
covers about 95% of the parasite’s surface thereby shielding other surface proteins from the 
host’s immune response (Schwede et al., 2015). Furthermore, VSGs can remove specific host 
anti-VSG antibodies from the cell surface thereby reducing the effect of the host’s antibody 
response (Engstler et al., 2007).  
1.5 Clinical symptoms of trypanosomiasis 
In humans, the early stages of trypanosome infection are known as the haemolymphatic phase 
during which the parasites are restricted to the blood and lymph system (Stijlemans et al., 
2015). Following an insect bite, infected patients may develop a local skin reaction caused by 
an inflammatory response. Early symptoms include fever due to successive waves of 
parasitaemia, headaches, weight loss, itching, weakness and pain in the joints. Immune 
responses also result in enlarged lymph nodes and spleen. The disease then develops to the 
meningo-encephalitic stage where the parasite crosses the blood-brain barrier and enters the 
central nervous system and cerebrospinal fluid, resulting in confusion, disturbed sleeping 
pattern, lethargy and a coma. The terminal phase of the disease is characterised by seizures 
and heart failure (Sternberg, 2004). If untreated, infected patients may die within months if 
infected with T. b. rhodesiense or within years if infected with T. b. gambiense (Steverding, 
2008).  
Cases of animal trypanosomiasis are usually chronic but acute cases also occur leading to 
death within a week of infection. Similar to HAT, there is usually swelling at the site of the 
insect bite which may remain unnoticed. Infected animals develop primary symptoms such as 
fever, weight loss, lymphadenopathy and anaemia (Steverding, 2008). Anaemia is diagnosed 
by the low packed volume of red blood cells. These cells undergo lysis due to the innate 
immune response or by haemolysins released by the parasite (Cooper et al., 2017). Further 
symptoms may include decreased milk production, neurological signs, cardiac lesions, 
diarrhoea, keratitis, loss of appetite, emaciation, weight loss and paralysis (Steverding, 2008).  
1.6 Diagnosis of trypanosomiasis 
An understanding of the epidemiology of trypanosomiasis and management of the disease 
depends on accurate diagnosis and distinction between the causative species. Clinical signs 
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and symptoms are the initial diagnosis of trypanosomiasis. In regions where HAT is endemic, 
presentation of clinical signs in patients suggests possible infection (Kennedy, 2013). In the 
case of AAT endemic areas, anaemia in cattle is usually an indication of infection (Auty et al., 
2015). Trypanosomes may also cause chancre which can be detected several days after a 
tsetse bite, however, not all trypanosome strains cause chancre. Additionally, the symptoms 
may be mistaken with that of other diseases such as diabetes or theileriosis in cattle thus 
making clinical diagnosis less reliable (Luckins and Gray, 1978). In addition to clinical signs, 
serological, parasitological and molecular tests are usually required for trypanosomiasis 
diagnosis.  
1.6.1 Parasitological diagnosis for trypanosomiasis 
Parasitological tests are based on standard microscopic detection of trypanosomes in blood 
samples or lymph node smears. These were the first parasitological tests done in endemic 
areas as parasites can be easily detected under a light microscope based on their morphology 
and light microscopy is still widely used for diagnosis of AAT (Dabo and Maigari, 2017). Thick 
blood smears can be used to detect the parasite but does not distinguish between 
trypanosome species. Thin smears, on the other hand, can be used to distinguish between 
the species based on morphology and wet mounts distinguish based on motility. T. vivax is 
characterised by rapid movements across the microscope slide while T. brucei moves in one 
place. T. congolense attaches onto red blood cells and moves in one place (Dabo and Maigari, 
2017).  
The sensitivity of the technique was improved by the removal of the red blood cells followed 
by concentration of the parasites by centrifugation prior to microscopic analysis. Later, a more 
sensitive technique was developed, the mini anion-exchange centrifugation technique 
(mAECT) based on the removal of blood cells from the test blood sample through anion 
exchange chromatography. This technique was reported to detect approximately 100 
trypanosomes per mL of blood and worked best for T. brucei and T. evansi spp. (Büscher, 
2002; Büscher et al., 2009; Büscher et al., 2017). 
The stage of HAT infection is determined by microscopic examination of the cerebrospinal 
fluid (CSF) obtained through a lumbar puncture. The presence of the parasite and an increase 
in white blood cell count are an indication of stage two HAT (Dabo and Maigari, 2017). Staging 
of HAT is crucial for treatment purposes as the second stage requires medication that can 
cross the blood-brain barrier. The sensitivity of this technique allows the identification of non-
HAT patients to ensure that they are not unnecessarily treated for second-stage HAT 
(Chappuis et al., 2005). However, false negatives can occur with this method of diagnosis, 
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particularly in T. b. gambiense infections where the parasite numbers are sometimes below 
the detection limit.  
1.6.2 Molecular diagnosis for trypanosomiasis 
Molecular diagnostic tests are based on the detection of the parasite’s DNA. Understanding 
the trypanosomes at a genomic level has led to the development of specific primers which can 
be used in a polymerase chain reaction (PCR) and loop-mediated isothermal amplification 
(LAMP) (Solano et al., 1999). The latter has advantages over PCR in that: partially processed 
or non-processed DNA template can be used therefore DNA extraction may not be required. 
It also uses a simpler heating device that maintains temperature and has a shorter 
amplification time (Njiru et al., 2011). Molecular diagnostic tests have been improved by the 
identification of DNA based markers that differentiate between trypanosome species and 
subspecies (Deborggraeve and Büscher, 2010).  
In the diagnosis of HAT, the molecular differentiation between T. b. gambiense and T. b. 
rhodesiense is based on two gene markers, i.e. T. b. gambiense specific glycoprotein which 
is only found in T. b. gambiense and serum-resistance-associated protein specific for T. b. 
rhodesiense (Gibson et al., 2002). The PCR system has also been used for the diagnosis of 
Chagas disease and these are based on the satellite DNA of T. cruzi (Abras et al., 2018).  
Both PCR and LAMP technology have also been used to identify the three AAT causative 
species. Specific primers for T. congolense, based on ribosomal P0 subunit protein, and T. 
vivax, based on satellite DNA, have been designed and used to diagnose AAT (Kuboki et al., 
2003; Njiru et al., 2011).  
It is evident that diagnosis depends on the identification of specific antigens. Both the DNA 
based techniques are useful in that they can directly detect the pathogen, but the parasitaemia 
can vary. Additionally, most of these molecular tests are not applicable to the resource-poor 
field settings therefore, appropriate serological tests are needed (Auty et al., 2015). 
1.6.3 Serological diagnostic methods for trypanosomiasis 
Trypanosome infection can also be indicated by the presence of specific antibodies in the 
blood, plasma or serum of the infected hosts. The serological tests are often based on VSGs 
because these proteins are highly immunogenic and expressed in higher levels compared to 
other trypanosome proteins. The sensitivity of antibody detection tests depends on the type of 
antigen(s) used. Serological tests detect antibodies three to four weeks after infection 
(Mugnier et al., 2016). 
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1.6.3.1 Serological diagnosis of human African trypanosomiasis  
Currently, there is a serodiagnostic test for T. b. gambiense infections available, the card 
agglutination test for trypanosomiasis (CATT), which detects specific antibodies against VSG 
variant LiTat 1.3 in the blood serum of infected individuals. This test has also been used to 
detect T. b. evansi infections by detection of RoTat 1.2 VSG (Ngaira et al., 2005). The card 
agglutination test, however, is associated with a few limitations which include a short shelf life 
and a requirement for electric power, therefore, cannot be used in rural areas (Jamonneau et 
al., 2015). 
Rapid diagnostic tests for T. b. gambiense infection include HAT- Sero-K- SeT and SD Bioline 
HAT 1.0 which detect antibodies against variable antigen types LiTat 1.3 and 1.5 VSGs 
(Büscher et al., 2013). The advantage of these diagnostic tests is that they comply with the 
ASSURED (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and 
deliverable to end users) criteria. Unfortunately, the T. b. rhodesiense strain does not express 
the LiTat 1.3 VSG, consequently, diagnosis still relies on clinical features and blood smears 
are used to confirm the diagnosis. Efforts towards the development of rapid diagnostic tests 
for both T. b. gambiense and T. b. rhodesiense are still on-going (Büscher et al., 2017). 
Although CATT and rapid diagnostic tests are useful in the screening and diagnosis of T. b. 
gambiense infections, these tests are not 100% accurate and give false negatives when the 
disease prevalence is low (0.1%) (Jamonneau et al., 2015). 
Other antibody detection tests include the complement fixation test (CFT), indirect fluorescent 
antibody (IFAT) test and enzyme-linked immunosorbent assay (ELISA) for both HAT and AAT 
diagnosis. ELISA has been used in epidemiological surveys to detect anti-trypanosome 
antibodies and is considered a reliable and easy immunological diagnostic method. It is 
sensitive, specific and can be applied to dry blood spots. However, the technique is based on 
either whole parasite or crude lysate as the antigen, making it difficult to standardise (Mugnier 
et al., 2016). 
1.6.3.2 Serological diagnosis of animal African trypanosomiasis 
There are non-variant molecules which have been identified as diagnostic targets and are 
immunogenic in mammalian hosts. A mitochondrial heat shock protein (HSP70) from T. 
congolense, a mammalian immunoglobin binding protein (BiP) homologue has been proposed 
as a potential diagnostic target. Immunoglobin binding protein homologues are also found in 
T. vivax and T. brucei (Boulangé et al., 2002). An inhibition ELISA based on the HSP70/BiP 
was able to detect primary infections in cattle challenged with T. congolense and T. vivax while 
further studies are required to validate this antigen as a diagnostic target for T. brucei (Bossard 
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et al., 2010). T. vivax infections have also been successfully detected in cattle using a lateral 
flow test based on invariant surface glycoprotein (ISG). Recombinant ISG was able to 
distinguish infected sera from non-infected sera in an immunoreaction, with equal sensitivity 
to an ELISA test (Fleming et al., 2016). A tandem repeat protein GM6 and cathepsin B-like 
cysteine protease were also identified as potential serodiagnostic targets for T. vivax and T. 
congolense infections respectively. However, the cathepsin B-like cysteine protease shares 
epitopes with the T. vivax homologues which results in cross-reactivity in a rapid diagnostic 
test (Boulangé et al., 2017). T. vivax recombinant cathepsin L-like cysteine proteases 
(TviCATL) was evaluated as a diagnostic antigen and could discriminate between T. vivax 
infected and non-infected cattle sera (Eyssen et al., 2018).  
Because anti-trypanosomal antibodies persist in the blood, ELISA does not specify whether 
the infection is current or whether the animals were cured of previous infection (Van den 
Bossche et al., 2000). Therefore, an alternative to antibody-based detection ELISA is antigen-
based detection ELISA. The latter detects specific antigens in the blood of infected hosts which 
is an indication of current infection. This approach was first used to diagnose Chagas disease 
using polyclonal antibodies. Polyclonal antibodies, however, have low specificity, thus the use 
of species-specific monoclonal antibodies was developed. These were successful in the 
detection of T. b. rhodesiense and T. b. gambiense infections in humans. Monoclonal 
antibodies have also been used in antigen-capture sandwich ELISA to detect T. congolense, 
T. vivax and T. brucei in the blood of infected cattle and goats. However, this type of test was 
also shown to give false negatives in acute or early infections. This is because the antibodies 
are directed at internal antigens which are only released after lysis of the parasite. As a result, 
antigen ELISAs are combined with parasitological tests for an accurate diagnosis. 
Furthermore, the use of recombinant antigens is a promising tool for the detection of 
trypanosome antibodies (Mugnier et al., 2016).  
1.7 Control measures for trypanosomes 
Accurate diagnosis followed by appropriate treatment are important for effective control of AT. 
This is a major challenge in the case of HAT as it is often under-diagnosed due to limited 
accuracy in diagnostic methods, insufficient numbers of skilled staff and the presence of an 
animal reservoir host, particularly for T. b. rhodesiense HAT. Control by surveillance has been 
identified as a useful technique. This is where a mass screening is done in areas identified as 
high risk, followed by treatment upon case detection (Büscher et al., 2017). Though the 
reported reduction in HAT cases in the past decade, there is limited access to remote areas 
and people are often reluctant to participate in the repeated screening activities which are a 
major challenge with this technique, making it less effective (Franco et al., 2014). 
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Tsetse vector control is considered a desirable method of AT control. The Pan African tsetse 
and trypanosome eradication campaign (PATTEC) together with the African Bank 
Development have partnered in an attempt to eliminate the tsetse vector by making funding 
available for this initiative (Holt et al., 2016). Since the 1980s vector control methods have 
included selected bush clearing, sequential aerial spraying, mobile and stationary traps 
treated with insecticides, sterile insect technique as well as treatment of cattle with 
insecticides. These are done by using either a field-by-field approach where the goal is to 
temporarily alleviate AT burden in a localised area or an area-wide approach where the aim 
is to eliminate the entire tsetse population in a geographical area (Vreysen et al., 2013). 
Although there are government charities and funding towards this initiative, a number of 
communities who are affected by the disease do not have enough resources for vector control 
and these programmes do not always reach them (Holt et al., 2016). 
1.7.1 Treatment of trypanosomiasis 
Vector control methods are expensive, especially when applied in large scale, therefore, most 
African farmers opt for trypanocidal drugs in the case of AAT (McDermott and Coleman, 2001; 
Giordani et al., 2016). Trypanocides are divided into two categories i.e. curative trypanocides 
which kill the parasite in the blood of infected animals but are not always 100% effective, and 
chemoprophylactic drugs which kill the parasites and remain in the blood to prevent new 
infections (Desquesnes et al., 2013).  
The use of trypanocides in the chronic phase of AAT does clear parasitaemia but the 
symptoms may take longer to subside. The commonly used curative drug is diminazene 
aceturate and is used to treat infections in cattle, sheep and goats. Diminazene is administered 
in high doses through intramuscular injections. This drug is active against T. evansi, T. 
congolense T. brucei and T. vivax and has few side effects (Desquesnes et al., 2013). Other 
drugs include isometamidine chloride, melarsomine dihydrochloride, suramin and 
quinapyramine which are used as prophylactic drugs. These drugs are often administered by 
the farmers themselves with no supervision which has contributed to the emergence of drug 
resistance, a major challenge since there is a limited number of drugs commercially available 
(Giordani et al., 2016). 
There are five drugs available for the treatment of HAT. The choice of drugs depends on the 
causative species and stage of the disease. Pentamidine and suramin are used to treat the 
first stage of HAT. Pentamidine is more effective against T. b. gambiense HAT while efficacy 
is limited in rhodesiense HAT (Simarro et al., 2012). Pentamidine is administered 
intramuscularly or intravenously. Suramin, on the other hand, is effective against both HAT 
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causing species but is only used to treat T. b. rhodesiense HAT due to the high risk of allergic 
reactions caused by the rapid killing of microfilaria (Kennedy, 2013). Early infections are easier 
to treat than second stage diseases because the latter requires drugs that cross the blood-
brain barrier, which may be toxic to the patient (Büscher et al., 2017). 
Melarsoprol, nifurtimox and eflornithine are used to treat the second stage of HAT. Melarsoprol 
is used to treat T. b. rhodesiense infections over a 10-day period of intravenous injections. 
Eflornithine is effective against T. b. gambiense infections and is administered intravenously 
over 14 days. Nifurtimox is used to treat Chaga’s and is not licenced in Africa but is used as 
an off-label treatment in west Africa, which requires authorisation by national authorities 
(Büscher et al., 2017). These drugs are associated with several issues of toxicity and 
resistance, therefore, efforts are continually being made for better and safer use (Babokhov 
et al., 2013). Additionally, there is limited availability of the drugs and they are often 
administered in large doses. A combinatory administration of the drugs may be a solution to 
these drawbacks. An example of this is nifurtimox-eflornithine combination therapy (NECT) 
which was found to have a higher curative rate and lower death rates compared to melarsoprol 
and eflornithine monotherapies (Büscher et al., 2017). A new oral drug, fexinidazole was 
shown to be effective against second stage T. b. gambiense HAT. This drug has a higher 
efficacy compared to NECT and is available at a low cost. However, it is also associated with 
adverse side effects such as vomiting and psychiatric disorders (Chappuis, 2018).  
The development of trypanocidal drug resistance is becoming a major problem in the 
treatment of trypanosomiasis. This is characterised by the loss of sensitivity to trypanocides 
even at doses recommended and under proper veterinary practises. These drugs have been 
in use for over 60 years and resistance has been reported in many areas. Resistance to 
trypanocidal drugs could be innate, which occurs naturally in hosts that have not been 
previously exposed to a drug, acquired resistance, which is a result of previous exposure or 
due to mutation in the parasite’s genome. Understanding the mechanism by which 
trypanosomes take up drugs is important for the development of new chemotherapeutic 
strategies (Melaku and Birasa, 2013). 
Drug resistance has been reported for one or more of the AAT drugs in more than 17 sub-
Saharan countries. Multiple resistance has also been reported for diminazene and 
isometamidine chloride used for AAT (Giordani et al., 2016). In the case of HAT treatment, the 
introduction of NECT reduced the chances of drug resistance (Büscher et al., 2017). 
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1.7.2 Trypanotolerance 
Trypanotolerance in cattle is defined as the ability to survive and remain productive during 
trypanosomal infections. It was first observed when cattle of taurine origin, N’Dama cattle (Bos 
taurus), were found to be less susceptible to trypanosomiasis (Murray et al., 1981). This field 
observation was confirmed in a comparative study between N’Dama and Boran cattle 
challenged with T. congolense which showed that N’Dama cattle remained productive, gained 
weight and had better control over parasitaemia and anaemia than the Boran breed (Paling et 
al., 1991).  
Since these findings, many studies have been directed towards understanding and identifying 
the genes associated with trypanotolerance and discovering processes that could help with 
the conference of these genes. A study by Hanotte et al. (2002) revealed that F2 calves 
derived from Boran and N’Dama contained five genes from Boran grandparents which were 
involved in trypanotolerance. This suggested that crossbreeding may be a useful approach 
not only to improve the trypanotolerance of N’Dama cattle but also in the control of 
trypanosomiasis (Naessens, 2006).  
Additionally, in the early stages of trypanosome infection, N’Dama cattle were found to 
produce high levels of IgG reactive with T. congolense and T. b. brucei lysosomal cysteine 
protease which was not the case in susceptible cattle. This cysteine protease is associated 
with the pathogenicity of the trypanosome parasite and has also been reported in other 
parasites (discussed in Section 1.8). Despite the higher levels of antibody response to other 
proteins in trypanotolerant cattle compared to susceptible cattle, antibody response to the 
cathepsin L-like cysteine protease was regarded a marker of trypanotolerance (Orenge et al., 
2012; Berthier et al., 2015). 
1.8 Proteases 
Proteases are enzymes which hydrolyse peptide bonds of proteins. Although all proteases 
cleave proteins, they differ in many characteristics including size, localisation, quaternary 
structure and the mechanism used to hydrolyse the substrate. These enzymes can be further 
classified according to the active site groups involved in the catalytic mechanism into seven 
classes i.e. serine, cysteine, aspartic, threonine, glutamic and metalloproteases as well as 
asparagine peptide lyases (Otto and Schirmeister, 1997). Among the proteases, cathepsins 
play a major role in proteolysis, particularly the aspartic, serine, and cysteine cathepsins 
(Lecaille et al., 2002). The majority of the cathepsins are cysteine proteases such as cathepsin 
B, C, F, H, K, L, S, V, X and W. Cathepsins D and E are aspartic cathepsins, and cathepsins 
A (also known as carboxypeptidase Y) and G are serine cathepsins (Turk and Turk, 2009). 
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1.8.1 Cysteine proteases 
The first cysteine (thiol) protease was isolated and characterised from a Carica papaya fruit, 
thus named papain. Since the discovery of papain, cysteine proteases that have a DNA 
sequence like papain are called “papain-like’’. Cysteine proteases are found in all living 
organisms, have a molecular mass of ~21-30 kDa and show optimum activity at pH 4 to 6.5 
(Turk et al., 1998). Sequences for several cysteine proteases have been identified in the 
human genome and parasitic organisms. These include the main groups of cysteine 
proteases: clan CA, clan CD and caspases. Clan CA is further subdivided into the C1 family 
(cathepsins B and L) known as papain-like cysteine proteases due to their similarities in 
structure, and C2 family (calpain). Most studies have been focused on papain-like cysteine 
proteases cathepsins B and L because they are found in a wide range of parasitic organisms. 
The mechanism of these proteases is well understood, which is an advantage in the process 
of drug discovery. Furthermore, it is believed that due to their similarities, a large inhibitor 
library may have possible leads for several parasitic diseases (Sajid and McKerrow, 2002). 
Cathepsin B is different from cathepsin L in that the pro-domain is about 30 amino acids 
shorter (Fig. 1.5, panel A) and an occluding loop is present. Furthermore, cathepsin L-like 
cysteine proteases have a conserved ERFNIN motif which is absent in cathepsin B (Turk et 
al., 1996; Lecaille et al., 2002). Papain contains two domains: an N-terminal domain with alpha 
helices and the C-terminal domain with beta sheets, with the catalytic domain located in 
between (Fig. 1.5, panel B). The active site residues are Cys25, His159 and Asn175 which are 
conserved among all cysteine proteases (Sajid and McKerrow, 2002) 
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Figure 1.5: Structural representation of the pro and mature domain of cysteine proteases. A, 
classification of the cysteine proteases and predicted lengths of the signal peptide, pro and mature 
domain. Accessed from http://www.sinobiological.com/cathepsin-enzyme.html. B, Ribbon diagram 
showing the N-terminal domain with alpha helices and the C-terminal domain with beta sheets. The 
catalytic residues Cys, His and Asn are shown as stick models. Adapted from Verma et al. (2016).  
 
Papain-like cathepsins are synthesised as inactive precursors (zymogens), to prevent 
unwanted protein degradation (Verma et al., 2016). They have a pro-domain and a mature 
(catalytic) domain (Fig. 1.5, panel A) linked by a few Phe and Tyr residues. The pro-domain 
prevents access to the active site by the substrate, thus acts as an endogenous inhibitor. It 
also assists in the folding of protein by acting as an intramolecular chaperone. Cysteine 
proteases may be secreted or targeted to intracellular compartments by an N-terminal signal 
peptide which comprises of ~15 - 22 hydrophobic amino acid residues (Sajid and McKerrow, 
2002).  
The interaction between the substrate and the cysteine protease substrate-binding pocket is 
best described by the Schechter and Berger diagram (Fig. 1.6). This diagram shows that 
substrate contains amino acid at positions P1, P2, P3 etc. N-terminal to the scissile bond and 
P’1, P’2, P’3 etc. C-terminal to the scissile bond and the protease contains subsite pockets S1, 
S2, S3, etc. and S’1, S’2, S’3 etc. which binds amino acids of the substrate in the corresponding 
positions (Schechter and Berger, 1967). The amino acids found on either side of the scissile 
bond are important for the specificity of the enzyme. Studies have shown that only five subsites 
are crucial for substrate binding: S1, S2 and S2’ bind the backbone and side-chain of the 
substrate while S3 and S2’ bind only the amino acid residue side chains (Turk et al., 2012). 
Cysteine proteases have substrate specificity at the S2 pocket and are sensitive to the class 
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specific cysteine protease inhibitor L-trans-epoxysuccinyl-leucyl- amido (4-guanidino) butane 
(E-64). Their catalytic mechanism is similar to that of serine proteases, but they have an 
additional shell of electrons in the thiol group, making them better nucleophiles than the 
hydroxyl group on serine proteases (Sajid and McKerrow, 2002). 
 
                         
Figure 1.6: Schematic representation of the interaction between enzyme and substrate 
illustrating the  Schechter and Berger (1967) nomenclature. Accessed from 
https://prosper.erc.monash.edu.au/methodology.html. 
  
1.8.2 Catalytic mechanism of cysteine proteases 
Proteases that cleave within the polypeptide are known as endopeptidases while those that 
cleave at the ends of the polypeptide are known as exopeptidases. Aminopeptidases cleave 
from the N-terminus and carboxypeptidases cleave from the C-terminus of the substrates. In 
cysteine proteases, pH changes play a critical role in the activation of the enzyme. Endo-
peptidases are activated via auto-activation which occurs in an acidic environment. During this 
process, the low pH in lysosomes disrupts the interactions between the pro-domain and 
mature (catalytic) domain, causing them to dissociate to release an active catalytic domain 
(Turk et al., 2012).  
The active enzyme must bind to the substrate prior to hydrolysis (Fig. 1.6). Catalytic residues 
His, Cys and Asn form the catalytic triad. The His residue acts as a proton donor while the 
thiol group in Cys acts as a nucleophile, forming an ion pair which is stabilised by Asn. This 
ion pair attacks the carbonyl group in the scissile bond of the substrate, resulting in a 
tetrahedral intermediate stabilised by an oxyanion hole formed by asparagine and a highly 
conserved glutamine residue. The tetrahedral intermediate transforms to an acyl enzyme and 
the C-terminal end of the scissile bond is cleaved off. The acyl enzyme is then hydrolysed by 
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water resulting in a second tetrahedral intermediate which ultimately splits into a free enzyme 
and N-terminal end of the substrate (Verma et al., 2016). 
                   
Figure 1. 7: Schematic representation of the catalytic mechanism of cysteine proteases. Accessed 
from http.researcs://wwwhgate.net/figure/Catalytic-mechanism-of-lysosomal-cysteine-proteinases-as-
exemplified-by-papain_fig1_26538859  
 
1.9 Parasite cysteine proteases 
Cysteine proteases have been reported in many parasites such as Plasmodium falciparum, 
which causes malaria (Rosenthal et al., 1988), Fasciola hepatica which is affects the intestines 
of mammalian hosts (Chung et al., 1995), Entamoeba hystolytica which causes amebiasis 
(Reed et al., 1993) and Caenorhabditis elegans which also affects the intestines of mammalian 
hosts (McKerrow, 1995). Many of these proteases are papain-like cathepsins B and L and 
play a major role in pathogenesis. The cysteine proteases of F. hepatica, E. hystolytica and 
C. elegans play a role in host tissue invasion and nutrient acquisition (Siqueira-Neto et al., 
2018). P. falciparum cysteine proteases have been reported to play a role in haemoglobin 
hydrolysis and red blood cell lysis. Furthermore, cysteine protease inhibitors were found to 
have antimalarial activity (Marco and Miguel Coteron, 2012). Studies have also shown the 
potential use of helminth cysteine proteases as drug targets. Mice which were challenged with 
lung or adult stage Schistosoma mansoni worms showed a decrease in worm burden following 
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treatment with cysteine protease inhibitors (fluoromethyl ketone and vinyl sulfone inhibitors 
(Caffrey et al., 2018).  
1.9.1 Trypanosomal cysteine proteases 
Many papain-like cysteine proteases have been reported in Leishmania and Trypanosoma 
parasite and the effects of specific inhibitors suggest their role in pathogenesis. Studies on T. 
brucei revealed that cathepsin L protects the parasite from degradation and opsonisation and 
assists in the crossing of the blood-brain barrier (Nikolskaia et al., 2006). Cathepsin B is found 
in the BSF of the parasite where it hydrolyses transferrin taken up from the host as part of the 
iron acquisition pathway (Siqueira-Neto et al., 2018). Other trypanosomal cysteine proteases 
which have been studied include rhodesain (from T. b. rhodesiense), cruzain (from T. cruzi), 
congopain (from T. congolense) and vivapain (from T. vivax) and were found to be the 
dominant antigens during infections. RNA interference of Trypanosoma brucei cathepsin B 
and L was also found to reduce the ability of the parasite to cross the blood-brain barrier and 
prolonged the survival period in mouse models (Abdulla et al., 2008). Vinyl sulfone K777, a 
potent cruzain inhibitor, was found to decreased parasite burden in animal models challenged 
with T. cruzi (Ferreira and Andricopulo, 2017).  
Trypanosomal cathepsin L-like cysteine proteases have a unique C-terminal extension (not 
found in mammalian homologues) which is highly immunogenic, thereby diverting the immune 
response away from the functional domain (Boulangé et al., 2001). Congopain (TcoCATL) and 
vivapain (TviCATL) protease activity have been shown to change during the different life cycle 
stages of the parasite with the BSF having the highest activity (Mbawa et al., 1992). These 
proteases are released into the bloodstream after parasite lysis where they contribute to 
pathogenesis associated with T. congolense and T. vivax infections. Trypanopain (TbbCATL) 
was found to be involved in pathogenesis by degrading various host proteins. This enzyme is 
also released into the bloodstream during T. b. brucei infections but unlikely to remain active 
due to the presence of host inhibitors (Troeberg et al., 1997). Furthermore, vinyl sulfones and 
peptidyl methyl-ketones which are novel irreversible inhibitors were shown to inhibit the activity 
of BSF TbbCATL (Troeberg et al., 1999). Consequently, trypanosomal cysteine proteases are 
thought to play a role in the parasite viability and are targets in chemotherapy and diagnostic 
developments.  
Trypanosomal cysteine proteases produce an antibody response which may not affect the 
survival of the parasite, however, they are believed to play a role in trypanotolerance by 
neutralising the effects of the enzyme. Therefore, the effects of antibodies on the enzyme 
activity have been investigated. Troeberg et al. (1997) reported the presence of both activity-
enhancing and activity-inhibiting antibody responses to TbbCATL due to the polyclonal nature 
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of the antibodies. On the other hand, anti-congopain IgG as well as antigen binding fragments 
(Fab) showed inhibitory effects on congopain activity against the peptide substrate Z-Phe-Arg-
AMC which indicate that host-specific antibodies may mitigate trypanosome pathology (Authié 
et al., 2001; Lalmanach et al., 2002). 
It is evident from the findings that cysteine proteases are desirable targets in the development 
of antigen based diagnostic tools. Although antigen-based diagnostic kits are an indication of 
current infection, the sensitivity of the tests depends on the number of circulating parasites 
antigen in the host. Furthermore, the target antigens must have epitopes specific to each 
Trypanosoma spp. Therefore, there is an additional requirement for capture antibodies which 
recognise the distinct epitopes on each antigen and do not interact with the host IgG antibodies 
resulting in false positives. This is often occurring from interactions with the constant Fc 
regions of the antibodies (Torres et al., 2018). This can be overcome by using substitute 
antibody molecules recruited from large libraries of peptides and functional domains of 
different proteins displayed on the surface of bacteriophages. This technology is known as 
phage display technology (discussed in Section 1.9) (Smith and Scott, 1993). 
1.10 Phage display technology 
Phage display technology is a method used to display polypeptides or proteins on the surface 
of filamentous bacteriophages (viruses that infect Gram negative bacteria). These phages are 
said to be “friendly” phages since they can assemble and replicate without killing the host cell. 
The polypeptide libraries presented on the surface of phages allow the selection of 
polypeptides, proteins and functional antibody fragments with high affinity and specificity to a 
target of interest (Arap, 2005). They are usually displayed as fusions with the phage coat 
proteins. This is achieved by fusing genes encoding polypeptides or proteins with genes 
coding the phage coat proteins thus allowing the simultaneous construction of large phage 
display libraries (up to 1010 variants) (Arap, 2005; Paschke, 2006).  
1.10.1 General biology of filamentous phages 
Bacteriophage species used in phage display technology include f1, fd, T4, M13 and T7. 
These phages are commonly used due to their potential as excellent cloning vehicles and their 
ability to correctly assemble longer phage particles in a simple manner. Phages have single 
stranded DNA (ssDNA) which encodes three classes of proteins: replication proteins, 
morphogenic proteins and structural proteins. Structural proteins make up a large component 
of the phage particles and are encoded by pIII, pVI, pVII, pVIII and pIX genes of the single 
stranded genome (Fig. 1.8). The pVIII gene encodes the major coat protein which makes up 
99% of the protein mass and the remainder is composed of the minor coat protein encoded 
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by pIII, pVI, pVII and pIX (Endemann and Model, 1995). The coat proteins act as anchors for 
the displayed polypeptide and do not interfere with peptide-ligand interaction (Paschke, 2006).  
 
                                   
Figure 1.8: Schematic representation of the filamentous phage M13 and coat proteins. The single 
stranded phage is encapsulated by 2 700 copies of the major coat proteins, pVIII and 5 copies of each 
of the minor coat proteins pIII, pVI, pIX and pVII (Løset et al., 2011).  
 
The most commonly used phages, such as the filamentous phage M13, use minor protein pIII 
and major protein pVIII as fusion proteins (Fig. 1.8) (Smith and Scott, 1993; Endemann and 
Model, 1995). The pIII library can display up to five copies of the display peptides while the 
pVIII can display up to 2700 copies of small peptides. Additionally, M13 phages can only 
display peptides and proteins that are able to pass through the bacterial membrane while 
maintaining the proper folding (Scott and Smith, 1990; Smith and Scott, 1993).  
1.10.2 Vectors in phage display technology 
In early studies, the genes of an antibody fragment or polypeptide were cloned directly into 
the phage genome. Since the phage displays three to five copies of the pIII minor coat protein, 
phage vectors often resulted in the display of multivalent copies of the antibody fragment or 
polypeptide, thereby decreasing the infectivity of the phage. Additionally, it is difficult to 
achieve high affinity selection with multivalent display vectors because they do not distinguish 
between weak and strong affinity ligands (Petrenko and Vodyanoy, 2003). An alternative 
approach was the use of phagemid vectors. Phagemid vectors are designed by combining the 
phage genome and portions of the plasmid. Like the phage vector, they contain essential 
structural components i.e. a promoter region, signal peptide, cloning site, detection and 
purification marker (tag), amber codon for expression, coat protein gene, origin of replication 
for filamentous phage, Escherichia coli replication origin and selection marker (antibiotic 
resistance gene) (Fig. 1.9). Phagemid vectors are mostly used because they have higher 
transformation efficiencies compared to phage vectors and allow for the construction of larger 
libraries. 
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The size of the expressed foreign protein limits the use of the phage. Although the pIII protein 
can be used to display large peptides, the infectivity of the phage is compromised. To 
overcome this, bacteria containing phagemid vectors are infected with a helper phage such 
as the M13KO7 helper phage. The helper phage contains all the genes required for packaging, 
infection, replication, assembly and budding of the phagemid, but has a low copy origin of 
replication which causes the helper phage to be replicated but packaged less effectively 
(Winter et al., 1994). The modified origin of replication is inserted into the native M13 origin of 
replication. During infection, the wildtype pIII from the helper phage competes with the pIII-
fusion protein from the phagemid for expression on the surface of the phage. The majority of 
the phages express the wildtype pIII protein (known as the “bald phages”) while only a few 
express the pIII-fusion protein.  
                                                            
Figure 1.9: Schematic representation of construction of phagemid vector for phage display 
library.  The vector contains an origin of replication of ssDNA (f1 ori), plasmid origin of replication for 
E. coli and antibiotic resistance gene (AR). It has a promotor (P), the display sequence (DS) cloned 
between the signal peptide (SP) and pIII coat gene. The amber codon (AC) is located between the DS 
and the pIII (Zhao et al., 2016).  
 
During protein synthesis, the amber codon recruits a tRNA carrying a complementary stop 
codon which signals termination of proteins synthesis. Certain cells produce a mutation in the 
DNA complementary to the amber codon, preventing the signal to terminate protein synthesis. 
Such cells are known as suppressors (Cropp and Schultz, 2004). In phagemids, the amber 
codon of protein synthesis is often inserted between the gene for pIII and the cloned fragment 
(Fig. 1.9). This allows the fragment and fusion protein to be expressed on the surface in 
suppressor cells, or expressed in the soluble form in non-suppressor E. coli cells 
(Hoogenboom et al., 1991).   
The pIII protein is located on the surface of the phage capsid and contains three functional 
autonomous domains i.e. D1 (at the C-terminus), D2 and D3 (at the N-terminus). During 
infection of E. coli, D1 translocates the viral DNA into the host cytoplasm, D2 binds to the 
bacterial F-pilus and D3 plays a role in capsid assembly and reproduction (Georgieva and 
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Konthur, 2011). The advantage of using pIII is that is allows incorporation and presentation of 
larger polypeptides compared to pVIII. Infection begins by binding of the phage to the pilus of 
the bacterium, followed by conversion of the ssDNA to dsDNA (replicative form) by 
cytoplasmic enzymes. The phage particles are assembled from the inner membrane of the 
bacterium and are secreted with the help of pVII and pIX (Rami et al., 2017). 
1.10.3 Phage display technology in antibody scFv fragment production 
Antibodies can bind a large variety of antigens with high affinity and specificity, and have 
important properties required for diagnostic development, however, due to their complexity, 
they cannot be produced in large amounts or functional forms in bacterial hosts. Additionally, 
the size of the displayed antibody may reduce the infectivity of the phage previously mentioned 
(Section 1.10.2) (Ruigrok et al., 2011). The immunoglobulin G (IgG) is a heterodimer which 
consists of two identical heavy and light chains linked by disulfide bonds (Fig. 1.10). 
Recombinant expression hosts do not have optimal conditions required for the expression of 
a complete antibody molecule therefore, antibody fragments are used in E. coli -based phage 
display systems. 
Different antibody fragments can be displayed on the surface of bacteriophages, these include 
the antigen binding fragment (Fab), variable fragment (Fv) and single chain variable fragments 
(scFv). The Fv is the smallest immunoglobulin fragment with antigen binding activity. Single 
chain variable fragment (scFv) consists of two Fv fragments of the heavy chain and light chain 
linked by a short peptide linker of about 25 amino acids to improve the stability of the scFv. 
The peptide linker consists of glycine, and serine or threonine amino acid residues, making it 
flexible and soluble (Kuhn et al., 2016). Despite the absence of the constant regions and 
addition of a peptide linker in scFvs, the specificity of the original immunoglobulin remains 
intact. Additionally, being half the size of the Fab with the same specificity as the parent 
immunoglobulin, scFvs are easy to express and have been successfully applied in techniques 
such as flow cytometry and immuno-histochemistry (Arap, 2005). 
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Figure 1.10: Schematic representation of the antibody and derived fragments. (Ig): 
immunoglobulin made up of the heavy chain (Y shaped), light chain, variable fragment (Fv); Fab 
(fragment antigen binding); Fc (fragment crystallisable), CH1-3 (constant regions of the heavy chain); 
CL (constant region of the light chain); scFv (single chain variable fragments) joined by a linker. 
Accessed from https://www.antibodies-online.com/resources/18/1502/antibody-and-immunoglobulin-
alternatives-part-1/ 
 
1.10.4 Phage display antibody libraries 
There are four main types of antibody phage libraries i.e. immune, naive, semi-synthetic and 
synthetic libraries. In immune libraries, the B-cells are isolated from the spleen of an 
immunised animal, the V genes from the IgG mRNA are cloned into the phage library vectors. 
The advantage of immune libraries is that the antibodies isolated have a high affinity to their 
specific antigen because affinity maturation has already occurred in the immune system of the 
immunised animal. This technique allows antibodies to be isolated and rapidly produced from 
a single immunised donor and further manipulated. Immune libraries have been produced 
from various species such as humans (Hoogenboom and Winter, 1992), chickens (Sixholo et 
al., 2011) and rabbits (Weber et al., 2017), however, due to ethical concerns, active 
immunisations are only possible in some experimental animals. Some animals may have 
tolerance towards the antigen making the procedure less effective. Furthermore, each antigen 
requires the construction of a new library which can be time consuming and costly, therefore, 
different types of non-immune libraries were introduced to overcome these limitations (Iba and 
Kurosawa, 1997). 
The non-immune libraries, also known as the “single pot’’ library, include the naive, synthetic 
and semi-synthetic libraries. They are constructed from B-cells isolated from the spleen of 
animals.  In a naïve library, the V genes are derived from the IgM mRNA of a non-immunised 
animal (Rami et al., 2017). The genes are amplified from the cDNA followed by random 
combination of the VH and VL genes which are cloned to form scFvs or a Fab. This technique 
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produces antibodies which have not been exposed to antigens, but can bind to different 
antigens including self, non-immunogenic as well as toxic antigens  (Hoogenboom et al., 
1998).  
Synthetic libraries are constructed by introducing diversity in the complementary determining 
region (CDR) of the hypervariable regions (Rami et al., 2017). The diversity can be 
manipulated to correspond to areas where diversity occurs naturally in the antibody repertoire. 
Most of the natural sequence and structural diversity occurs in CDR3 of the heavy chain, 
making it a target for the introduction of diversity, while the other five CDRs have limited 
diversity (Conrad and Scheller, 2005). This library has an advantage over naïve libraries, 
where rearrangement of the V genes occurs naturally because the antibody repertoires can 
be constructed in a manner that allows optimum performance of the library. Semi-synthetic 
libraries are constructed by substituting the amino acids of the CDR regions which are involved 
in the binding of antigen to produce a library with high diversity that does not exist in vivo (Zhao 
et al., 2016). 
The most successful use of these libraries is in the screening and selection of monoclonal 
antibody fragments from a large library (Winter et al., 1994; Ahmad et al., 2012). To achieve 
this, the phages are constructed and released from the host in large amounts to ensure the 
likelihood of the desired fragment being present. This is determined by the binding capacity of 
the fragment to a specific ligand (Rakonjac, 2012).    
1.10.5 Biopanning 
Once the V genes are cloned into phagemid vectors, a variety of scFvs are displayed on the 
surface of the phage. These phages are then allowed to interact with an antigen of interest to 
select for specific clones with high affinity for the antigen in a process known as biopanning 
(or panning for short) (Petrenko and Vodyanoy, 2003). The high affinity antibodies are 
enriched by several rounds of panning, normally three to five rounds. There are many 
procedures that have been described for the panning of phages but the most common is done 
on the immobilised antigen (Hoogenboom et al., 1998). 
The panning process includes binding of the antigen onto a solid surface, followed by a 
blocking step, incubation of phage with the immobilised antigen followed by a washing step to 
remove non-specific phages. The phages are eluted and infected in bacterial cells for 
amplification of eluted phages (Fig.1.11). The bound phages are eluted with either an acidic 
buffer or with a basic buffer (Ruigrok et al., 2011). Other methods of elution include the use of 
dithiothreitol, enzymatic cleavage at the cleavage site inserted between the antigen and the 
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phage or addition of excess antigen to outcompete the bound phages (Carmen and Jermutus, 
2002).  
 
               
Figure 1.11: Phage cycle and biopanning (Ruigrok et al., 2011) 
 
During the first round of panning, the number of phages that bind is far less than the number 
that does not bind. Therefore, this round requires a high enough concentration of the antigen 
to increase the chances of selecting specific clones which may be present in low 
concentrations. These clones are amplified in E. coli  and used for subsequent panning rounds 
(Carmen and Jermutus, 2002). After panning, the phages are then screened using 
immunoassays or immunocytochemistry with the purpose of isolating those with high affinity 
to the target antigen (Ruigrok et al., 2011). 
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1.11 Aims and objectives of the study 
1.11.1 General objective 
Cysteine proteases from T. congolense, T. vivax and T. b. brucei have been identified as 
potential diagnostic targets for AAT. The main objective of this study was to produce 
antibodies which can be used for antigen-based specific diagnosis of T. b. brucei infection, 
targeting the cysteine protease (TbbCATL). Previous studies of TbbCATL were conducted on 
the native form of the enzyme and there are no reports on the recombinant form. The 
homologues from T. congolense and T. vivax have been recombinantly expressed and purified 
in their truncated form (excluding the C-terminal extension). 
1.11.2 Aims 
1. To clone and explore recombinantly expressing TbbCATL in bacteria to avoid possible 
intellectual property restrictions of the Pichia pastoris expression vectors. In addition, 
TcoCATL and TviCATL were recombinantly expressed in P. pastoris.  
2. To produce anti-TbbCATL antibodies in chickens and analyse their cross-reactivity with, 
TcoCATL and TviCATL in a western blot.  
3. To optimise phage display technology as an alternative to animal-based antibody 
production. The Nkuku® phage library was used to select for scFvs specific for TviCATL for 
potential use in a rapid diagnostic test.  
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Chapter 2 
Cloning, recombinant expression and purification of trypanosomal 
cysteine proteases from T. b. brucei (TbbCATL), T. congolense 
(TcoCATL) and T. vivax (TviCATL) 
 
2.1 Introduction 
Trypanosoma congolense, T. vivax and T. b. brucei cause animal African trypanosomiasis 
(AAT) or nagana which is an economic burden and hampers agricultural development in Africa 
(Muhanguzi et al., 2017). The parasite escapes the host’s immune response by switching 
genes coding for the variable surface glycoproteins, resulting in new variable antigen types. 
This has made it unlikely to develop a vaccine against the disease and therefore many studies 
now focus on identifying trypanosome antigens as potential drug targets (Giordani et al., 
2016). Studies on T. congolense revealed that the cathepsin L-like cysteine protease, 
TcoCATL, is involved in the pathogenesis by degrading host proteins (Serveau et al., 2003). 
In addition, trypanotolerant N’Dama cattle were found to have high levels of IgG against 
TcoCATL in their blood serum. These antibodies were believed to contribute to 
trypanotolerance by inhibiting TcoCATL activity, thus this enzyme is considered a possible 
candidate for an anti-disease vaccine to limit the symptoms of the disease, such as anaemia, 
rather than killing the parasite  (Authié et al., 2001). 
Trypanosoma brucei brucei cathepsin L-like cysteine protease (TbbCATL) shares sequence 
identity with TcoCATL and homologues from T. vivax (TviCATL) as well as TcrCATL from T. 
cruzi, the parasite that causes Chagas disease in humans in South America. This suggests 
that these cathepsins may be similarly involved in pathogenesis and are sought as potential 
drug targets. Like other clan CA cysteine proteases, these proteases contain a pro-domain, 
catalytic domain and a unique C-terminal extension which does not occur in mammalian 
cysteine proteases (Boulangé et al., 2011). The C-terminal extension, whose function is not 
yet understood, is linked to the catalytic domain by a proline rich hinge in the case of TcoCATL 
and TbbCATL, and a threonine rich hinge in TviCATL (Fig. 2.1). The catalytic residues Cys25 
and His191 (TcoCATL numbering) are spatially positioned to form an ion pair which is stabilised 
by Asn211 during substrate hydrolysis (Sajid and McKerrow, 2002). 
Since the sequencing of the cysteine protease TbbCATL from T. b. brucei cDNA (Mottram et 
al., 1989), this protease has been isolated, purified and characterised through substrate 
specificity and inhibition studies (Troeberg et al., 1999). These studies were done on the native 
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protease and to date, there are no reports on recombinantly expressed TbbCATL. Although 
recombinant expression of an active full length and truncated TcrCATL was previously 
reported in E. coli (Eakin et al., 1993), recombinant expression of TcoCATL has been confined 
to the 28 kDa catalytic domain excluding the C-terminal extension as it is highly immunogenic 
(Authié et al., 2001). This expression was done in the methylotrophic yeast, Pichia pastoris 
which was reported to yield more TcoCATL compared to bacterial expression systems. In light 
of this, TviCATL, excluding the C-terminal extension, has also been recombinantly expressed 
in P. pastoris and both proteases have been enzymatically characterised (Boulangé et al., 
2011; Eyssen et al., 2018). 
There are many advantages of using P. pastoris, however, the AOX 1 requires methanol for 
induction which can be toxic to the cells and is flammable. Yeast cells require a longer biomass 
generation time prior to the induction phase and switching from glucose as a carbon source 
in the growth phase to methanol in the induction phase at the exact time is difficult. 
Additionally, there are possible intellectual property restrictions on the P. pastoris vector if the 
produced antigens are to be used for diagnostic assays (Juturu and Wu, 2018). Therefore, the 
E. coli expression is usually the first expression system to be explored because it is quick and 
inexpensive to culture and high protein yields can be obtained at small scale due to the strong 
promoter. Competent E. coli cells can be stored and thawed before use whereas yeast cells 
must be used immediately and requires screening of many colonies to select a good producer 
as protein yield can vary among clones. Furthermore, in E. coli proteins are expressed with a 
purification tag that can also be used to detect the expressed protein using commercial 
antibodies (Bill, 2014). 
Cloning vectors that allow C-terminal or N-terminal positioning of fusion tags are available. 
Fusion tags can either be peptide tags which include poly-Arg, poly-His, FLAG, or non-peptide 
tags which include maltose-binding proteins (MBP) and glutathione S-transferase (GST) 
(Terpe, 2003). These tags are useful in the detection of recombinantly expressed proteins by 
western blots, especially when the expressed protein is too small to be identified by SDS-
PAGE analysis. 
In this chapter, TbbCATL was cloned, recombinantly expressed in E. coli BL21 (DE3) using 
the pGEX-4T vector which adds a 26 kDa GST tag and purified. pET32a and pET28a were 
also used for expression and the results are reported in this chapter. Recombinant expression 
and purification of TcoCATL and TviCATL in P. pastoris is also reported. Further details of the 
diagnostic target are reported in chapter 3.  
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TcrCATL       -----MSGWARFVLLAAVLVVMACLVPAATASLHAEETLTSQFAEFKQKHGRVYESAAR- 54 
TviCATL      -------MHAH--ALVTLLAAAVSVAPAAMAVLRADGPVEPLFAAFKQKYGRSYGTAAEE 51 
TbbCATL      MPRTEMVRFVR--LPVVLLAMAACLASVALGSLHVEESLEMRFAAFKKKYGKVYKDAKEE 58 
TcoCATL      MPRSEMTRTLR--FSVGLLAVAACFVPVALGVLHAEQSLQQQFAAFKQKYSRSYKDATEE 58 
                       :    . :*.  .... .* . *:.:  :   ** **:*:.: *  * .  
 
TcrCATL      RLPLSVFRENLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAQERARVP 114 
TviCATL      AFRLRVFEDNMRRSRMYAAANPHATFGVTPFSDLTPEEFRTRYHNGERHFEAARGRVRTL 111 
TbbCATL      AFRFRAFEENMEQAKIQAAANPYATFGVTPFSDMTREEFRARYRNGASYFAAAQKRLRKT 118 
TcoCATL      AFRFRVFKQNMERAKEEAAANPYATFGVTRFSDMSPEEFRATYHNGAEYYAAALKRPRKV 118 
              : : .*.:*:  ::  *****:****** ***:: ****: *:**  :: **  * *   
 
TcrCATL      VKVEVVGAPAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQML 174 
TviCATL      VQVPPGKAPAAVDWRRKGAVTPVKDQGTCGSCWSFSAIGNIEGQWAAAGNPLTSLSEQML 171 
TbbCATL      VNVTTGRAPAAVDWREKGAVTPVKVQGQCGSCWAFSTIGNIEGQWQVAGNPLVSLSEQML 178 
TcoCATL      VNVSTGKAPEAVDWRKKGAVTPVKDQGQCGSCWAFSAIGNIEGQWKVAGHELTSLSEQML 178 
             *:*    ** ***** :**** ** ** *****:**:***:* **  **: *..****** 
 
TcrCATL      VSCDKTDFGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATIT 234 
TviCATL      VSCDTKDNGCGGGLMDNAFEWIVKENSGKVYTEKSYPYVSGGGEEPPCKPRGHKVGATIT 231 
TbbCATL      VSCDTIDSGCNGGLMDNAFNWIVNSNGGNVFTEASYPYVSGNGEQPQCQMNGHEIGAAIT 238 
TcoCATL      VSCDTNDFGCEGGLMDDAFKWIVSSNKGNVFTEQSYPYASGGGNVPTCDKSGKVVGAKIR 238 
             ****. * ** ****::**:***..* * *:** ****.** *  * *   *: :** *  
 
TcrCATL      GHVELPQDEAQIAACVAVNGPVAVAVDASSWMTYTGGVMTSCVSEQLDHGVLLVGYNDSA 294 
TviCATL      GHVDIPHDEDAIAKYLADNGPVAVAVDATTFMSYSGGVVTSCTSEALNHGVLLVGYNDSS 291 
TbbCATL      DHVDLPQDEDAIAAYLAENGPLAIAVDAESFMDYNGGILTSCTSKQLDHGVLLVGYNDNS 298 
TcoCATL      DHVDLPEDENAIAEWLAKNGPVAIAVDATSFQSYTGGVLTSCISEHLDHGVLLVGYDDTS 298 
             .**::*.**  **  :* ***:*:**** ::  *.**::*** *: *:********:*.: 
 
TcrCATL      AVPYWIIKNSWTT-QGEEGYIRIAKGSNQCLVKEEASSAVVGGPGPTPEPTTTTTTSAPG 353 
TviCATL      KPPYWIIKNSWSSSWGEKGYIRIEKGTNQCLVAQLASSAVVGGPGPTPTPTPT------- 344 
TbbCATL      NPPYWIIKNSWSNMWGEDGYIRIEKGTNQCLMNQAVSSAVVGGPTPPPPPPPP------- 351 
TcoCATL      KPPYWIIKNSWSKGWGEEGYSALRR-HNQCLMKNLPSSAVVSGPP-----PPP------- 345 
               *********:.  **.**  : :  ****: :  *****.**                 
 
TcrCATL      PSPSYFVQMSCTDAACIVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHCS 413 
TviCATL      -TNNNNNND-------------RTWPIVKLHEDA-------------LQR---------- 367 
TbbCATL      -PSATFTQDFCEGKGCTKGCSHATFPTGECVQTTGVGSVIATCGASNLTQIIYPLSRSCS 410 
TcoCATL      -PTPTFTQELCEGAECQSKCTKATFPTGKCVQLSGAGSVIASCGSNNLTQIVYPLSSSCS 404 
                    :               * *  :    :             * .           
 
TcrCATL      GPSVRSSVPLNKCNRLLRGSVEFFCGSSSSGRLATWTGSVAISHTTAVIAASEGTLCF 471 
TviCATL      ---------------------------------------------------------- 367 
TbbCATL      GPSVPITVPLDKCIPILIGSVEYHCSTNPPTKAARLVPHQ------------------ 450 
TcoCATL      GFSVPLTVPLDKCLPIVIGSVMYECSDKAPTESARLVRHE------------------ 444 
 
Figure 2.1: Sequence alignments of cathepsin L-like cysteine proteases from T. b. brucei 
(TbbCATL), T. congolense (TcoCATL), T. vivax (TviCATL) and T. cruzi (TcrCATL). The sequences 
were aligned using Clustal Omega multiple sequence alignment tool. TbbCATL accession number 
CAA34485.1, TcoCATL accession number AAA18215.1, TviCATL accession number CCD21670.1, 
TcrCATL accession number AACC00067.1. The N-terminal pro-domain sequence (11-12 kDa) is 
enclosed in the green shape, catalytic domain sequence (28-31 kDa) is enclosed in the red shape and 
the C-terminal extension sequence (11-13 kDa) is enclosed in the purple shape. The catalytic residues 
C, H and N are indicated by the arrows. The predicted Asn glycosylation site for T. vivax is underlined 
within the catalytic domain. The peptide sequences highlighted in blue were used in antibody production 
(discussed in Chapter 3). 
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2.2 Materials and methods 
2.2.1 Materials 
Molecular Biology: High fidelity PCR enzyme mix, GeneJet™ Plasmid Miniprep kit, 
O’geneRuler™ 1Kb DNA Ladder, 5-bromo-4-chloro-3-indolyl-β-D-galactopyronoside (IPTG), 
isopropyl-β-D-thiogalactopyronoside (X-gal), T4 DNA ligase and PTZ57R/T were purchased 
from Themo Scientific (USA). Zymo Research DNA clean and concentrator™5 kit was 
purchased from ZymoResearch (USA). BamHI, XhoI, InsTAclone PCR cloning kit and 
TransformAid™ Bacterial Transformation kit were purchased from Fermentas (Vilnius, 
Lithuania). The E.Z.N.A® gel extraction kit was from PEQlab biotechnology (Germany), 
pGEM®_T cloning vector was purchased from Promega (Madison, WI, USA) and pET32a and 
pET28a were purchased from Novagen (Darmstadt, Germany). pGEXT-4T was purchased 
from GE Healthcare (Uppsala, Sweden). FIREpol® Taq polymerase, 10 x PCR reaction buffer 
and 25 mM MgCl2 were obtained from Solis Biodyne (Tartu, Estonia). Crystal violet and 
ethidium bromide were from Sigma-Aldrich (USA). Seakem® LE agarose was purchased from 
Lonza (USA) and tryptone, yeast extract and bacteriological agar were purchased from Merck 
(Darmstadt, Germany). Ampicillin was purchased from Amresco (USA) and kanamycin from 
Life Technologies (UK). 
Escherichia coli cells: E. coli strains JM109 and BL21 (DE3) were purchased from New 
England Biolabs (Ipswitch, MA, USA). E. coli JM109 allows blue/white colony screening of 
transformants in the presence of IPTG and X-gal, while E. coli BL21 (DE3) lacks Lon and 
OmpT protease expression (Miroux and Walker, 1996). 
Antibodies: Mouse anti-6xHis IgG-horseradish peroxidase (HRPO) and rabbit anti-chicken 
IgY-HRPO detection antibodies were from Sigma-Aldrich (USA) and chicken anti- glutathione-
S-transferase (GST) IgY antibodies were produced in-house.  
Glycerol stocks of plasmid containing TviCATL and TcoCATL genes: Glycerol stocks of 
P. pastoris GS115 containing TviCATL was obtained from Professor Theo Baltz (University of 
Victor Segalen, Bordeaux, France) and TcoCATL was from Dr Alain Boulangé (University of 
KwaZulu-Natal, Pietermaritzburg). Tetracycline, yeast nitrogen base (without amino acids) 
and biotin were purchased from Sigma-Aldrich (USA). 
Protein purification and quantification: Glutathione-agarose resin was purchased from 
Sigma-Aldrich (USA). The HiPrep® Sephacryl® S-200 HR prepacked column and ÄKTA prime 
plus were purchased from GE Healthcare (Uppsala, Sweden). Tertiary butanol and 
ammonium sulfate were from Sigma-Aldrich (USA). Phosphorylase B (97.4 kDa), bovine 
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serum albumin (66 kDa), ovalbumin (45 kDa) and carbonic anhydrase (30 kDa) were 
purchased from Sigma-Aldrich (USA). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blot analysis: Hydrogen peroxide (H2O2) and 2-mercaptoethanol were purchased from Merck 
(RSA). PageRuler pre-stained marker was purchased from Separation Scientific (SA), 
BioTrace™ nitrocellulose was from PALL Life Sciences (USA) and 4-chloro-1-naphthol was 
from ThermoScientific (Walthem, USA).  
Peptide substrates and inhibitors: The peptide substrate Z-Phe-Arg-amino-4-
methylcoumarin (AMC), H-D-Val-Leu-Lys-AMC and L-trans-epoxysuccinyl-leucylamido (4-
guanidino) butane (E-64) were purchased from Sigma-Aldrich (USA).  
2.2.2 Bradford Assay for protein quantification 
The Bradford dye-binding assay (Bradford, 1976) was done to determine the concentration of 
the purified proteins. A 1 mg/ml stock solution of ovalbumin was used to construct a standard 
curve (Fig. 2.2). Triplicate samples of 20-100 µg/ml in 100 µl dH2O were prepared, 900 µl of 
the Bradford dye reagent [0.6% (w/v) Coomassie brilliant blue G-250 in 2% (v/v) perchloric 
acid] was added and mixed by vortexing and incubated for 5 min at RT. The absorbance was 
measured at 595 nm.  
                          
Figure 2.2: Bradford dye-binding assay standard curve. The standard curve was constructed from 
ovalbumin standards ranging from 20-100 µg/ml and allowed to interact with the Bradford dye reagent 
[0.6% (w/v) Coomassie brilliant blue G-250 in 2% (v/v) perchloric acid]. The absorbance was measured 
at 595 nm. The trend line equation was y=0.0122x + 0.0346 with a correlation coefficient of 0.99.                         
 
2.2.3 Cloning of TbbCATL into pGEM®-T and PTZ57R/T TA cloning vectors 
The primers for amplification of the gene coding for the catalytic domain of T. b. brucei 
cathepsin L-like protease were: forward primer: 5’-GC GGATCC ATG GCG TGC CTT GCG 
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TCT GTC G-3’ and reverse primer: 5’- GC CTCGAG TCA ACT GCG GAG ACG GCC TG -3’. 
The restriction site for BamHI (forward) and XhoI (reverse) are underlined. 
Genomic DNA of T. brucei available in our laboratory was used as a template for the 
amplification of the TbbCATL gene. The PCR master mix contained TbbCATL Fw and Rv 
primers (0.25 µM for each), 1x High Fidelity PCR enzyme mix buffer, 2.5 mM MgCl2, 0.25 U 
High Fidelity Taq polymerase and 0.5 mM dNTPs in a 20 µl reaction volume for 35 cycles with 
the conditions listed in Table 2.1.  A sample of the PCR product (5 µl) was analysed by gel 
electrophoresis (Section 2.2.4). The remaining sample was purified using Zymo Research 
DNA gel recovery kit according to the manufacturers’ instruction manual. To determine which 
cloning vector works best, the purified TbbCATL gene fragment was ligated into pGEM®-T and 
PT757R/T cloning vectors (Fig. 2.3) in a 3:1 ratio of gene insert to vector using 6 U of T4 DNA 
ligase and incubated at 37°C for 1 hour followed by RT for 16 hours. 
 
Figure 2.3: TA cloning vector maps. (A) pGEM®-T (Promega); (B) PTZ57R/T (Thermo Fisher 
Scientific) 
 
Table 2.1: PCR conditions for amplification of the TbbCATL gene from genomic DNA 
Cycle step Temperature (ºC) Duration 
Initial denaturation 94 3 min 
Denaturation 94 30 s 
Annealing 53 30 s 
Extension 72 1 min 
Final extension 72 10 min 
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2.2.4 Gel electrophoresis for DNA analysis 
A sample of the PCR product (5 µl) was electrophoresed on a 1% (w/v) agarose gel containing 
0.5 µg/ml ethidium bromide in Tris-Acetate-EDTA (TAE) buffer (40 mM Tris-HCl, 100 mM 
acetic acid, 1 mM Na2EDTA, pH 8.0). The image was captured using the G:Box system 
(Syngene, Cambridge UK). A standard curve for the molecular weight marker separated on a 
1% agarose gel was constructed (Fig. 2.4). 
 
                                       
Figure 2.4: Standard curve for relative mobility against log of base pairs used in agarose 1% 
gels. Commercial O’geneRuler™ 1kb DNA Ladder was used in agarose gel electrophoresis. The 
trendline equation was given by y=-0.04579x+1.7916 with a correlation coefficient of 0.99.  
                                    
2.2.5 Transformation of recombinant TbbCATL_pGEM®-T and TbbCATL_PTZ57R/T into 
E. coli JM109 cells and colony PCR 
The ligation mixture was transformed into E. coli JM109 cells using the TransformAid™ 
bacterial transformation kit according to the manufacturer’s instruction manual, plated onto 
pre-warmed 2xYT medium [1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl, 
containing 1% (w/v) bacteriological agar, 20 µg/ml X-gal, 50 µg/ml ampicillin and 1 mM IPTG] 
and incubated at 37ºC overnight. A mixture of blue and white colonies was obtained from 
which a white colony was randomly selected and resuspended in 10 µl of sterilised distilled 
water. The colony mixture (2 µl) was used in colony PCR which was carried out (as per Section 
2.2.3, with 5 U FIREPol® Taq polymerase) in a 50 µl reaction volume for 25 cycles using the 
conditions shown in Table 2.2. A sample of the PCR product was electrophoresed on a 1% 
(w/v) agarose gel containing 0.5 µg/ml ethidium bromide. From the remaining colony mixture, 
2 µl was inoculated in 6 ml 2xYT broth medium containing 50 µg/ml ampicillin and incubated 
at 37ºC overnight, with agitation (200 rpm). 
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Table 2.2: Colony PCR conditions for amplification of TbbCATL in expression vectors 
Cycle step Temperature (ºC) Duration (min) 
Initial denaturation 95 5 
Denaturation 95 1 
Annealing 58 1 
Extension 72 2 
 
2.2.6 Plasmid isolation and restriction digestion 
From the overnight culture, 1 ml was used to make glycerol stocks, stored at -80ºC and the 
remainder was used for plasmid isolation which was carried out using the GeneJet plasmid 
mini-prep kit according to the manufacturer’s instructions. The purified plasmid was double 
digested with BamHI and XhoI in a 30 µl reaction volume at 37ºC for 1 hour. The enzymes 
were inactivated by incubation at 70ºC for 20 min. A 10 µl sample from the reaction was 
electrophoresed on a 1% (w/v) agarose gel and the remaining sample was electrophoresed 
on a 1% (w/v) agarose gel containing 10 µg/ml of crystal violet. The gene insert was extracted 
from the latter gel using the Zymo Research DNA gel recovery kit, as per the manufacturer’s 
instructions.  
2.2.7. Ligation of the TbbCATL gene into pET32a, pET28a and pGEX-4T expression 
vectors and transformation into E. coli BL21 (DE3) cells 
A sample of the genes were sent for sequencing at the University of Stellenbosch Central DNA 
sequencing Facility and the insert from PTZ57R/T was chosen for further use as it has fewer 
mutations. The ligation was carried out in a 5:1 ratio of gene inserts to expression vector (Fig. 
2.5) using T4 DNA ligase in a 30 µl reaction, at 37ºC for 1 hour followed by RT for 16 hours. 
The ligation mixtures, TbbCATL_pET32a, TbbCATL_pET28a and TbbCATL_pGEX-4T were 
transformed into E. coli BL21 (DE3) cells. Briefly, competent E. coli BL21 (DE3) cells were 
thawed on ice, 2 µl of the ligation mixture was added to 80 µl of the competent cells and 
incubated on ice for 30 min. The cells were heat shocked at 42ºC for 45 s and returned to ice 
for 2 min. The cells were added to 1 ml of pre-warmed 2xYT medium without antibiotic and 
incubated for 1 hour at 37ºC with shaking (200 rpm). The cells were spread onto pre-warmed 
2xYT agar containing ampicillin for pGEXT-4T and pET32a, or kanamycin for pET28a and 
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incubated at 37ºC overnight. Colony PCR was carried out on randomly selected colonies using 
the conditions described in Table 2.2. Glycerol stocks were made and stored at -80ºC. 
 
           
        
 
Figure 2.5: Cloning regions of pET32a, pET28a and pGEX-4T vectors. (Novagen and Genscript 
technical manuals). 
 
2.2.8 Recombinant expression of TbbCATL_pET32a, TbbCATL_pET28a and 
TbbCATL_pGEX-4T in E. coli BL21 (DE3) cells 
Glycerol stocks made from the colonies containing recombinant plasmids after sub-cloning of 
TbbCATL in E. coli BL21 (DE3) were streaked onto 2xYT medium containing 1% (w/v) 
bacteriological agar and 50 µg/ml ampicillin and incubated at 37ºC overnight. A single colony 
was inoculated into 5 ml of 2xYT broth medium containing 50 µg/ml of ampicillin and incubated 
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at 37ºC with shaking at 200 rpm for 16 hours. A 1:100 dilution of the culture was done using 
fresh 2xYT medium (4 x 50 ml) and grown until it reached an OD600 of 0.6. Recombinant 
expression was induced with 100 mM IPTG for 4 hours, followed by centrifugation (6000 x g, 
4ºC, 10 min). The pellets were combined and resuspended in 8 ml of PBS containing 1% (v/v) 
Triton-X-100 and 1 µg/ml lysozyme and incubated at 37ºC for 1 hour. The pellet was frozen at 
-70ºC and thawed at RT. The lysed pellet was sonicated five times for 20 s on ice and 
centrifuged (10 000 x g, 4ºC, 10 min). The rest of the bacterial lysate was kept for purification 
while a 50 µl sample was analysed by SDS-PAGE. The expected size of TbbCATL including 
the purification tag in pET28a was 38 kDa, pET32a was 50 kDa and pGEX-4T was 58 kDa 
(Fig. 2.6). 
                        
Figure 2.6: Schematic representation of the expected TbbCATL sizes in the expression vectors. 
Recombinant expression in pET28a includes a His tag; pET32a includes a thioredoxin (Trx) and a His 
tag; pGEX-4T includes a GST tag. The S-tag is depicted by the yellow box 
 
2.2.9. TbbCATL recombinant expression analysis by 12% reducing SDS-PAGE 
The expression samples were analysed on SDS-PAGE according to the method described by 
(Laemmli, 1970). A sample (50 µl) from the bacterial lysate was combined with an equal 
volume of reducing treatment buffer [125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol, 10% 
(v/v) 2-mercaptoethanol] and boiled for 5 min followed by centrifugation (10 000 x g, 5 min, 
RT) using a benchtop centrifuge. The pellet was resuspended with an equal volume of PBS 
and reducing treatment buffer. A total of 10 µl of each sample was loaded onto a duplicate 
12% reducing SDS-PAGE gels (Laemmli, 1970) and electrophoresed at 100V, 20A per gel in 
tank buffer [250 mM Tris-HCl buffer, pH 8.3, 192 mM glycine, 0.1% SDS] using the BioRad® 
Mini protein electrophoresis apparatus (BioRad, USA). One gel was stained with Coomassie 
blue R250 and the other gel used for a western blot. The images were captured using the 
G:Box system (Syngene, Cambridge UK). A standard curve for the molecular weight marker 
separated on a 12% SDS-PAGE was constructed (Fig. 2.7). 
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Figure: 2.7 Standard curve for relative mobility against molecular weight marker used in 12% 
SDS-PAGE. The molecular weight marker was made up of phosphorylase B (97.4 kDa), bovine serum 
albumin (66 kDa), ovalbumin (45 kDa) and carbonic anhydrase (30 kDa). The trendline equation was 
given by y=-1.0718x+2.4147 with a correlation coefficient of 0.98.  
 
2.2.10 Western blot analysis of TbbCATL recombinant expression.   
After reducing SDS-PAGE, the gel was equilibrated with blotting buffer [45 mM Tris-HCl buffer, 
pH 8.3, 173 mM glycine and 0.1% (w/v) SDS] for 15 min with gentle shaking at RT. The gel 
was transferred onto a nitrocellulose membrane using blotting buffer for 16 hours, 20A. The 
unoccupied sites on the nitrocellulose were blocked with 5% (w/v) low fat milk in Tris buffered 
saline (TBS; 20 mM Tris-HCl buffer, pH 7.4, 200 mM NaCl) for 1 hour at RT with gentle shaking 
followed by a washing step with TBS. The nitrocellulose membrane was incubated with 
chicken anti-GST IgY (1 µg/ml) for 4 hours at RT, followed by a washing step with TBS before 
incubation with rabbit anti-IgY-HPRO conjugate for 1 hour at RT. Finally, the membrane was 
incubated in substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.1% (w/v) methanol, 
0.0015% (v/v) H2O2 in TBS] and incubated in the dark for 3 min and the image captured using 
the G:Box system (Syngene, Cambridge UK). 
2.2.11 Purification of recombinant TbbCATL 
Glutathione-agarose resin was suspended in distilled water and allowed to swell to a volume 
of 1 ml (max) at RT for 1 hour. The resin was transferred into a 10 ml BioRad® column and 
washed with 20 ml PBS followed by equilibration with 20 ml PBS containing 1% (v/v) Triton X-
100. The E. coli lysate was transferred to the column and incubated on an end-over-end rotor 
at 4ºC overnight. The column was washed with 20 ml of PBS-Triton-X, and 1 ml fractions were 
collected. The protein was eluted with reduced glutathione buffer (50 mM Tris-HCl, 10 mM 
reduced glutathione, pH 9.5). The column was regenerated with 5 ml sodium borate buffer 
(200 mM borate in 500 mM NaCl pH 8.0) and washed with 5 ml dH2O, followed by 5 ml sodium 
acetate buffer (100 mM acetate, 500 mM NaCl, pH 4.0) and 5 ml dH2O and stored in 40% (v/v) 
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ethanol at 4ºC.  The eluted fractions were analysed on a 12% reducing SDS-PAGE gel and 
stained with Coomassie blue R250 (Section 2.2.9). 
2.2.12 Recombinant expression and purification of cathepsin L-like cysteine proteases 
from T. congolense (TcoCATL) and T. vivax (TviCATL). 
TcoCATL and TviCATL genes were previously cloned into pPIC9 yeast expression vectors 
and transformed into P. pastoris GS115 (Pillay et al., 2010; Eyssen et al., 2018). The glycerol 
stocks were streaked onto yeast extract peptone dextrose (YPD) plates [1% (w/v) yeast 
extract, 2% (w/v) peptone, 2% (w/v) dextrose, 1% (w/v) bacteriological agar containing 10 
µg/ml tetracycline] and incubated at 30 °C for three days. A single colony was inoculated into 
100 ml of YPD liquid medium [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose 
containing 10 µg/ml tetracycline] and incubated for 2 days at 30ºC with shaking (200 rpm). 
The culture was added to 450 ml of buffered medium glycerol yeast (BGMY) [1% (w/v) yeast 
extract, 2% (w/v) peptone, 100 mM potassium phosphate buffer pH 6.5, 1.3% (w/v) yeast 
nitrogen base (YNB) without amino acids, containing 10 µg/ml tetracycline and 50 µg/ml 
ampicillin] and incubated in baffled flasks at 30ºC for 3 days with shaking (200 rpm). The 
BGMY culture was centrifuged (2000 x g, 4ºC, 10 min) and the resulting pellet resuspended 
in 500 ml buffered minimal media (BMM) [100 mM potassium phosphate buffer pH 6.5, 1.3% 
(w/v) YNB, 0.0004% (w/v) biotin, 0.5% methanol, containing 10 µg/ml tetracycline and 50 
µg/ml ampicillin]. The baffled flasks were covered with three layers of sterile cheese cloth, 
incubated as previously and supplemented with 0.5% methanol every 24 hours for seven days. 
The culture was centrifuged (2000 x g, 4ºC, 10 min) and the resulting supernatant was filtered 
through Whatman number 4 filter paper in preparation for protein purification.  
The recombinant proteins were purified by three phase portioning (TPP) (Pike and Dennison, 
1989). To the filtered supernatant, 30% (v/v) of tertiary butanol was added and mixed 
thoroughly. Ammonium sulfate was added to the mixture, 30% (w/v) for TcoCATL and 40% 
(w/v) for TviCATL and stirred until dissolved. The mixture was centrifuged (6000 x g, 4ºC, 10 
min) in a swing out rotor. The interfacial supernatant was carefully removed and the remaining 
TPP mixture was repeatedly centrifuged to ensure complete separation from the other phases 
and the pellets were resuspended in PBS. 
2.2.13 Purification of TcoCATL and TviCATL by molecular exclusion chromatography 
(MEC). 
The proteins were further purified by molecular exclusion chromatography (MEC). The 
HiPrep® 16/16 Sephacryl® S-200 HR (16 x 600 mm) pre-packed column was prepared 
according to the manufacturer’s instruction manual and connected to the ÄKTA prime plus 
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purifier. The column was equilibrated with 60 ml of Milli-Q® distilled water, followed by two 
column volumes (140 ml) of MEC buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) at 1 ml/min 
flow rate and 0.2 MPa pressure. The protein sample was filtered through a 0.22 µm filter and 
injected into the column (0.5 ml/min, 0.2 MPa, 120 ml). An elution profile (Fig. 2.8) was 
previously done by Dr Rob Krause to construct a calibration curve to determine the relationship 
between the molecular weight and elution volume of proteins of known size and the newly 
purified proteins. Fractions (2 ml) were collected and analysed by 12% reducing SDS-PAGE 
gel and silver stained (Section 2.2.14). 
                  
 
Figure 2.8: Elution profile for the calibration of the MEC column and Fischer’s plot for protein 
size estimation. A, The standard protein mix was loaded onto the Sephacryl S-200 HR column (0.5 
ml/min, 0.2 MPa, 120 ml) and eluted in MEC buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0), A, blue 
dextran (200 kDa), B: sheep IgG (130 kDa), C: BSA (66 kDa) and D: ovalbumin (45 kDa), E: myoglobin 
(14 kDa). B, the elution volumes of the standard proteins were plotted against their log molecular weight 
to construct the Fischer’s plot calibration curve with the trend line equation of y=-0.0462x+4.9321 and 
correlation coefficient of 0.99. 
 
2.2.14 Silver staining 
Silver staining is a sensitive staining method used to visualise small amounts of proteins. This 
was carried out according to the procedure described by Nesterenko et al. (1994). Following 
SDS-PAGE, the gel was placed in a clean glass container and incubated in a fixation solution 
[0.8% (w/v) trichloroacetic acid (TCA) and 0.015% (v/v) formaldehyde in 50% (v/v) acetone] 
for 5 min at RT with gentle shaking. The gel was washed with dH2O for 5 min before incubation 
with 50% acetone for 5 min at RT with gentle shaking followed by incubation in pre-treatment 
solution [0.01% (w/v) Na2S2O3·5H2O] and washing with dH2O. The gel was incubated in 
impregnate solution [0.26% (w/v) AgNO3 and 0.37% (v/v) formaldehyde] for 8 min at RT with 
gentle shaking, washed with dH2O for 10 s and incubated in developing solution [0.02% (w/v) 
Na2CO3, 0.015% (v/v) formaldehyde, 0.004% (w/v) Na2S2O3·5H2O] until protein bands were 
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visible and immediately immersed in stopping solution [1% (v/v) glacial acetic acid] and rinsed 
with dH2O. 
2.2.15 Active site titration of GST-TbbCATL, TcoCATL and TviCATL. 
In order to determine the active concentration of the purified GST-TbbCATL, TcoCATL and 
TviCATL, active site titration was conducted according to Barrett and Kirschke (1981). The 
proteases [1 µM diluted in 0.1% (w/v) Brij-35] were incubated with different concentrations of 
the cysteine protease inhibitor E-64 (0-1 µM) diluted in 0.1% (w/v) Brij-35 in assay buffer [100 
mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 6 mM DTT] and incubated for 30 min at 
37°C. The substrate Z-Phe-Arg-AMC (20 µM) for GST-TbbCATL and TcoCATL or H-D-Val-
Leu-Lys-AMC (20 µM) for GST-TbbCATL and TviCATL was added and fluorescence (Ex360nm; 
Em460nm) was measured using the FLUOStar Optima spectrophotometer (BMG Labtech, 
Germany). 
2.3 Results 
2.3.1 Cloning of the TbbCATL gene into the pGEM®-T and pTZ57R/T cloning vectors 
The 954 bp gene coding for the catalytic domain of the T. b. brucei cathepsin L-like cysteine 
protease (TbbCATL) was identified from the T. b. brucei genome. The gene was amplified by 
PCR using genomic DNA and showed a band of ca. 1000 bp (Fig. 2.9) which corresponds to 
the size of the target gene. 
                                                 
Figure 2.9: Agarose gel analysis of the TbbCATL PCR product amplified from T. b. brucei 
genomic DNA. TbbCATL gene was amplified with gene specific primer and analysed on a 1% agarose 
gel. M, molecular weight marker; lanes 1 and 2, TbbCATL PCR product; lane 3, non-template control.  
 
The gene fragment was extracted from the agarose gel and ligated into both pGEM®-T and 
PTZ57R/T cloning vectors and subsequently transformed into E. coli JM109 cells. To confirm 
the presence of the TbbCATL gene fragment in the vectors, the gene was amplified by PCR 
using specific gene primers in pGEM®-T and PTZ57R/T vectors. Analysis of the PCR product 
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on an agarose gel showed a band at ca. 1000 bp (Fig. 2.10, panel A) which correspond to the 
target gene’s size. Following isolation of the plasmids from the E. coli cells and restriction 
enzyme digestion with BamHI and XhoI restriction enzymes, the gene bands were observed 
at ca. 1000 bp, and plasmid bands were observed at ca. 3000 bp for both pTZ57R/T and 
pGEM-T as expected (Fig. 2.10, panel B). 
               
 
Figure 2.10: Colony PCR of TbbCATL_PTZ57R/T and TbbCATL_pGEM®-T in E. coli JM109 and 
restriction digestion analysis on 1% agarose. A, the TbbCATL gene insert was amplified specific 
from TbbCATL_PTZ57R/T and TbbCATL_pGEM®-T using gene specific primers. B, Recombinant 
TbbCATL_PTZ57R/T and TbbCATL_pGEM®-T plasmids were digested with BamHI and XhoI and 
compared to undigested plasmids. M, molecular weight marker. 
 
2.3.2 Transformation of recombinant TbbCATL_pET28a, TbbCATL_pET32a and 
TbbCATL_pGEX-4T expression vectors into E. coli JM109 cells. 
The recombinant plasmids were transformed into E. coli JM109 cells. The success of 
transformation was determined by analysis of the amplification product using specific gene 
primers. TbbCATL_pET28 and TbbCATL_pGEX-4T showed amplification ca. 1000 bp (Fig. 
2.11, panels A and B respectively) which corresponds to the target gene size. No amplification 
was observed from TbbCATL_pET32a (result not shown). 
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Figure 2.11: Analysis of TbbCATL gene amplification in recombinant pET28a and pGEX-4T after 
transformation into E. coli JM109 cells. Randomly selected colonies were amplified with gene 
specific primers in colony PCR and analysed on a 1% agarose gel. A, TbbCATL_pET28a E. coli 
transformant. B, TbbCATL_pGEX-4T E. coli transformant. M; molecular weight marker  
 
A sample of each plasmid was subjected to a small-scale restriction digestion using BamHI 
and XhoI as done previously and subsequently analysed on an agarose gel. For each vector 
a band was obtained at ca. 1000 bp and another band ca 3000 bp for pET32a, 6000 bp for 
pET28a and 5000 bp for pGEX-4T vectors (Fig. 2.12, panels A, B and C), which further 
confirmed the presence of the TbbCATL gene insert in the expression vectors. 
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Figure 2.12: Analysis of restriction digestion of the TbbCATL gene from TbbCATL_pET32a, 
TbbCATL_pET28a and TbbCATL_pGEX-4T clones using BamHI (fwd) and XhoI (rev). The 
samples were electrophoresed on a 1% agarose gel. A, restriction digestion of TbbCATL gene insert 
from pET32a. B, restriction digestion of the TbbCATL gene insert from pET28a, C, Restriction digestion 
of the TbbCATL gene insert from pGEX-4T. M; molecular weight marker.  
 
2.3.3 Transformation of TbbCATL_pET32a, TbbCATL_pET28a and TbbCATL_pGEX®_4T 
recombinant clones into E. coli BL21 (DE3) cells. 
The plasmids isolated from E. coli JM109 cells were transformed into E. coli BL21 (DE3) cells. 
Eight colonies were randomly selected and used as templates in colony PCR using T7 
promoter and terminator vector primers and specific gene primers and analysed by agarose 
gel electrophoresis. Amplification was only obtained with gene specific primers for 
TbbCATL_pET32a at ca. 1000 bp and TbbCATL_PGEX-4T between 500 and 750 bp (Fig. 
2.13, panels A and C respectively). The TbbCATL gene in the pET28a vector was amplified 
with vector primers at ca. 1000 bp and gene specific primers between 500 and 750 bp (Fig. 
2.13, panel B).  
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Figure 2.13: Agarose gel analysis of E. coli BL21 (DE3) transformed with TbbCATL_pET32a, 
TbbCATL_pET28a and TbbCATL_pGEX®_4T recombinant clones. Eight colonies were randomly 
selected and amplified with either T7 promoter and terminator vector primers (left hand panels) or gene 
specific primers (right hand panels) in a colony PCR. A, TbbCATL in pET32a; B, TbbCATL in pET28a; 
C, TbbCATL in pGEXT-4T. M, molecular weight marker. 
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2.3.4 Recombinant expression of TbbCATL in E. coli BL21 (DE3) cells. 
Analysis of recombinant expression of TbbCATL in E. coli BL21 (DE3) cells by reducing SDS-
PAGE (Fig. 2.14) showed that there were no prominent protein bands observed for 
TbbCATL_pET32a (expected at 50 kDa) (Fig. 2.14, panel A). A prominent band was observed 
for TbbCATL_pET28a expression at 66.5 kDa (expected at 38 kDa) (Fig. 2.14, panel B), but 
this band was not recognised by anti-His-tag antibodies (see below). The samples were also 
passed through a nickel column and no protein binding was observed. A prominent band was 
also observed at ca. 60 kDa when TbbCATL was expressed in pGEX-4T (Fig. 2.14, panel C). 
Analysis of the soluble and insoluble fractions showed that GST-TbbCATL was expressed in 
the soluble fraction (Fig. 2.14, panel C).  
A western blot was done to detect the His tag in TbbCATL_pET32a and TbbCATL_pET28a, 
and the GST tag from TbbCATL_pGEX-4T. There were no bands detected by the mouse anti-
6xHis-HRPO antibody (Fig. 2.14, panels A and B). The GST tag was detected in all the pGEX-
4T expression fractions, including the non-induced fraction of TbbCATL_pGEXT-4T (Fig. 2.14, 
panel C). A prominent band at ca. 60 kDa was observed in the induced and soluble fractions, 
which confirms soluble expression of GST-TbbCATL in pGEX-4T.  
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Figure 2.14: Analysis of the recombinant expression of TbbCATL on a 12% reducing SDS-PAGE 
gel and by western blot. Recombinant expression was induced in A, pET32a; B, pET28a and C, 
pGEX-4T. Samples were analysed on a 12% reducing SDS-PAGE, stained with Coomassie blue R-
250. In a western blot, proteins were transferred onto a nitrocellulose and incubated with mouse anti-
6xHis HRPO conjugate (Panels A and B); anti-GST IgY (Panel C) (primary antibody) followed by rabbit 
anti-IgY- HPRO (secondary antibody) and H2O2/4-chloro-1-naphthol. M, molecular weight marker. 
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2.3.4.1 Purification of GST-TbbCATL using glutathione agarose affinity 
chromatography 
Following recombinant expression of soluble GST-tagged TbbCATL (Fig. 2.14, panel C), the 
crude bacterial lysate was purified using glutathione agarose affinity chromatography and the 
eluted fractions were analysed by reducing SDS-PAGE (Fig. 2.15). Recombinant GST-
TbbCATL was eluted as a single band of approximately 60 kDa in fractions 1 to 10 (Fig 2.15, 
panel B) with reduced glutathione buffer. 
                     
 
Figure 2.15: Analysis of purification of GST-TbbCATL by GST affinity chromatography analysed 
on a 12% reducing SDS-PAGE gel. The samples were collected in 1 ml fractions at RT. A, PBS-Triton 
X-100 was used for binding of protein to the column and the washing step. B, Elution of protein with 
reduced glutathione buffer [50 Mm Tris-HCl buffer, pH 9, containing 10 mM reduced glutathione]. M, 
molecular weight marker. 
 
2.3.5 Recombinant expression and purification of the catalytic domain of T. congolense 
(TcoCATL) and T. vivax (TviCATL) 
TcoCATL and TviCATL were recombinantly expressed in P. pastoris yeast cells over two 
rounds of expression and recombinantly expressed proteins were analysed by reducing SDS-
PAGE (Fig. 2.16). TcoCATL was observed at the expected size of approximately 29 kDa. After 
round two of expression, the intensity of this band increased, indicating increased levels of 
expression. Two additional bands were observed between 31 kDa and 66.5 kDa. TviCATL 
was observed as two bands of approximately 28 kDa and 32 kDa. 
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Figure 2.16: Recombinant expression of TcoCATL and TviCATL analysed by 12% reducing SDS-
PAGE. The proteins were purified by three phase partioning prior to analysis. R1, round 1 of expression; 
R2, round 2 of expression; M, molecular weight marker. 
 
2.3.5.1 Purification of recombinant TcoCATL and TviCATL by molecular exclusion 
chromatography (MEC) 
The recombinant TcoCATL and TviCATL were further purified by Sephacryl S-200 MEC. For 
TcoCATL, protein absorbance peaks were observed at 40 ml and between 62 and 90 ml (Fig 
2.17, panel A) which corresponds to the expected size of 29 kDa. For TviCATL, protein 
absorbance peaks were observed at 40 ml and between 60 ml and 100 ml (Fig. 2.18, panel 
A) which correspond to the expected sizes of 28 kDa and 32kDa. Analysis by reducing SDS-
PAGE and silver staining showed a single band corresponding to the size of TcoCATL (30 
kDa) in fractions 72 to 86 ml (Fig. 2.17, panel B). The two bands at 28 kDa and 32 kDa 
corresponding to TviCATL were eluted together in fractions 80 to 88 ml (Fig. 2.18, panel B). 
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Figure 2.17: Purification of TcoCATL on a Sephacryl® S-200 HR molecular exclusion 
chromatography column. TcoCATL was loaded onto the column (16 x 600 mm, flow rate of 0.5 ml/min,  
2 ml/fraction, 120 ml) and eluted with MEC buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0). A, Elution 
profile of the 2 ml fractions at 280 nm. B, analysis of fractions 62 – 90 ml a 12% reducing SDS-PAGE 
gel followed by silver staining. M; molecular weight marker. 
 
 
Figure 2.18: Purification of TviCATL on a Sephacryl® S-200 HR molecular exclusion 
chromatography column. TviCATL was loaded onto the cloumn (16 x 600 mm, flow rate of 0.5 ml/min,  
2 ml/fractions, 120 ml) and eluted with MEC buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0). A, Elution 
profile of the 2 ml fractions at 280 nm. B, analysis of fractions 62 – 88 ml on a 12% reducing SDS-
PAGE gel followed by silver staining. M; molecular weight marker.   
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To estimate the active concentrations of the purified samples, an active site titration was done 
with E-64. Residual activity of GST-TbbCATL and TcoCATL hydrolysis of Z-Phe-Arg-AMC and 
GST-TbbCATL and TviCATL hydrolysis of H-D-Val-Leu-Lys-AMC substrates in the presence 
of E-64 was determined by measuring the absorbance of the released AMC. TcoCATL and 
TviCATL were able to cleave their respective substrates in the absence of E-64, while the 
addition of E-64 inhibited their activity in a dose dependant way (Fig. 2.19). Approximately 
20% of TcoCATL was active which is equivalent to 0.2 µM (Fig. 2.19, panel A) and 
approximately 30% TviCATL was active which is equivalent to 0.3 µM (Fig. 2.19, panel B). No 
activity was observed for GST-TbbCATL. 
 
 
Figure 2.19: Active site titration of TcoCATL and TviCATL. TcoCATL and TviCATL (1 µM) were 
titrated against E-64 ranging from 0-1 µM and incubated for 30 min at 37°C before incubation with A, 
Z-Phe-Arg-AMC and B, H-D-Val-Leu-Lys-AMC respectively. The mean residual activity against the 
substrates was measured (each data point represents the mean activity of triplicate samples).  
 
2.4 Discussion 
Cysteine proteases of trypanosomes have been discovered to play a crucial role in the 
pathogenicity of the parasite (Sajid and McKerrow, 2002). They are immunodominant and 
predominantly expressed during the mammalian infective stage of their life cycle, therefore 
are attractive diagnostic and drug targets (Serveau et al., 2003). In this study, cathepsin L-like 
cysteine proteases of the animal infective trypanosoma species T. b.i brucei (TbbCATL), T. 
congolense (TcoCATL) and T. vivax (TviCATL) were recombinantly expressed and purified. 
Moreover, cloning and recombinant expression of TbbCATL is reported for the first time in this 
study. 
The TbbCATL gene sequence was identified and amplified from the Lister 427 strain of T. b. 
brucei, and ligated into pGEMT and PTZ57/R TA cloning vectors. The gene sequence in 
PTZ57R had fewer mutations hence the fragment was used in further sub-cloning procedures. 
The pET vectors with a 6xhistidine tag (His-tag) are usually the first choice for recombinant 
protein expression in E. coli. Despite the possibility of decreased solubility of the fusion protein, 
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the pET vectors are desirable because of high protein expression levels in E. coli hosts due 
to a strong promoter, the His tag is small (in pET28a) and requires a simple purification method 
such as the nickel affinity chromatography and does not interfere with downstream 
applications of the expressed protein (Rosano and Ceccarelli, 2014). In light of this, pET28a 
was the first vector system to be investigated for recombinant expression of TbbCATL, 
followed by pET32a which has a Trx tag and a His-tag and lastly pGEX-4T which has a GST 
tag. Amplification with gene specific primers in a PCR showed that the DNA insert was only 
present in pET28a and pGEX-4T. A study by Álvarez et al. (2002) revealed that the use of 
gene specific primers may give false positives due to the direct amplification of non-cloned 
DNA fragments which enter the competent cells, together with recircularised plasmids, during 
transformation, hence, the presence of the TbbCATL gene in the vectors was confirmed with 
restriction digestion which showed that the gene insert was also present in pET32a. 
There was no expression obtained with the pET vectors in this study even after optimisation 
of temperature, induction time and IPTG concentration. In previous studies, attempts to 
recombinantly express TcrCATL using common vectors that use T7 and tac promoters was 
also unsuccessful, therefore this protease was expressed in the pCheYl5LOX expression 
plasmid. This vector expresses insoluble CheY fusion proteins which was required for the 
expression of significant amounts in the case of TcrCATL (Eakin et al., 1993). There are no 
reports on the use of pET vectors for the expression of TcoCATL. 
Due to the failed expression in the pET vectors the pGEX-4T vector was used and high levels 
of TbbCATL was expressed in soluble form. Expression was also observed in the non-induced 
sample which may be due to leaky expression. According to Terpe (2003), the majority of GST 
fusion proteins are expressed in the soluble form while others are partly soluble. The 
purification of the expressed GST-TbbCATL fusion protein required optimisation of the lysis 
method and incubation time of the bacterial lysate with the glutathione-resin. However, 
subsequent attempts to express TbbCATL resulted in an insoluble protein. Insoluble 
expression of GST fusion proteins is often associated with hydrophobic regions, many charged 
amino acid residues and large fusion proteins (≥100 kDa) (Terpe, 2003). In this case, however, 
factors that contributed to the insolubility of the protein remain unclear. Furthermore, attempts 
to purify the protease after solubilisation  were unsuccessful, therefore subsequent studies, 
i.e. antibody production and ELISAs, were carried out using the GST tagged TbbCATL. 
Previous attempts to express TcoCATL in bacterial systems resulted in an incorrectly folded 
and inactive protease which led to the investigation and optimisation of expression in P. 
pastoris (Boulangé et al., 2001). One of the main advantages of using the methylotrophic yeast  
P. pastoris is that recombinantly expressed proteins are secreted into the medium. The 
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secretion signal α-MF contains a pre-region which directs the protein to the endoplasmic 
reticulum (ER) and a pro-region which plays a role in the transfer of the protein from the ER 
to the Golgi apparatus. Secretion is efficient for the production and purification of proteins 
(Ahmad et al., 2014).  
In a study by Mendoza-Palomares et al. (2008), cathepsin B-like cysteine proteases, TcoCB, 
was recombinantly expressed in methyloptrophic yeast P. pastoris  as a highly glycosylated 
enzyme and the non-glycosylated mutant forms were obtained by disruption of glycosylation 
sites. The full length and truncated form of T. b. rhodesiense cathepsin L-like cysteine 
proteases has also been expressed in P. pastoris (Caffrey et al., 2001). In both studies, the 
pro-domain was included as it was shown to help with the proper folding of the enzyme. In the 
present study, the P. pastoris expression system was not investigated for TbbCATL however 
may be an ideal expression system for this protease. The primers that would be required for 
this are: forward primer 5’- GC CTCGAG ATG GCG TGC CTT GCG TCT GTC G -3’, reverse 
primer 5’- GC GAATTC TCA ACT GCG GAG ACG GCC TG -3’ with restriction sites for XhoI 
(forward) and EcoR1 (reverse) which are underlined. 
Trypanosomal cysteine proteases TcoCATL and TviCATL were expressed using the 
methylotrophic P. pastoris expression system. The expression was carried over two rounds 
and interestingly, the second round of expression yielded higher levels of TcoCATL. Generally, 
in this expression system, the growth phase is separated from the production phase, therefore 
the accumulated biomass is not stressed by the expressed protein. Nevertheless, during the 
production phase, the biomass continues to accumulate which may account for the higher 
levels of expressions of TcoCATL in the second round (Ahmad et al., 2014). However, this 
also resulted in higher levels of expression of yeast proteins as depicted by additional bands 
on reducing SDS-PAGE gels. 
TviCATL was expressed as two proteins bands (28 kDa and 32 kDa) which is consistent with 
the observation reported by Eyssen et al. (2018) where it is shown that the 32 kDA form is 
glycosylated. This protease is predicted to undergo N-glycosylation at Asn288 (TviCATL 
numbering) resulting in a mixture of glycosylated (32 kDa) and non-glycosylated (28 kDa) 
TviCATL. Glycosylation was also reported in TcrCATL and the glycosylation site is also found 
in the homologue found in Trypanosoma brucei rhodesiense (TbrCATL). In TcoCATL, the Asn 
is replaced by an Asp residue which explains why this protease is not glycosylated. 
In this study, TcoCATL and TviCATL were first purified by three-phase partitioning (TPP) 
before molecular exclusion chromatography (MEC). Generally, the contaminants are 
partitioned in the t-butanol and aqueous phase while the biomolecules are purified from the 
interphase during TPP (Dennison and Lovrien, 1997). In a study by Caffrey et al. (2001), 
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purification of TbrCATL was carried out on the P. pastoris culture supernatent using a 
lyophilisation step followed by a clearing step using an acidic buffer to remove enzyme 
proforms and contaminants and lastly a buffer exchange step. The recombinantly expressed 
pro-enzyme TcoCATB included a His-tag which allowed for purification by immobilised metal 
ion affinity chromatography (IMAC). The enzyme was activated in a low pH buffer and the 
catalytic domain purified by ion-exchange chromatography (Mendoza-Palomares et al., 2008). 
Three phase partitioning has been reported to enhance the activity of other proteins while it 
denatures proteins with the quaternary structure such as haemoglobin. Moreover, this 
technique has been used in the purification of proteases from microbial and plant sources 
(Nitsawang et al., 2006). TcoCATL and TviCATL were recovered at 30% and 40% (w/v) 
ammonium sulfate respectively, which is within the range of optimum parameters reported for 
other proteolytic enzymes (Gagaoua and Hafid, 2015).   
The activity of the purified TcoCATL and TviCATL proteases was studied using fluorogenic 
peptide substrates and a class-specific protease inhibitor, E-64. Consistent with the findings 
reported by Eyssen et al. (2018), TviCATL was able to hydrolyse H-D-Val-Leu-Lys-AMC. This 
protease prefers basic amino acid residues Lys and Arg in P1 position and bulky hydrophobic 
residues (Phe or Leu) in the P2 position. These results also show that the glycosylation in 
TviCATL does not affect enzyme activity. The activity of TcoCATL was studied using the 
standard substrate Z-Phe-Arg-AMC. Studies have shown that TcoCATL prefers substrates 
with Pro in P2, which is a characteristic of trypanosomal cysteine proteases that distinguishes 
them from their mammalian homologues (Boulangé et al., 2001). E-64 was able to inhibit the 
activity of TcoCATL and TviCATL as expected. In a study by Troeberg et al. (1996), the native 
TbbCATL succesfully cleaved the synthetic substrate Z-Phe-Arg-NHMec. In the present study, 
no activity was observed with recombinant TbbCATL on the synthetic substrate Z-Phe-Arg-
AMC. It is recommended that the fusion tag be removed from recombinant proteins prior to an 
activity assay as they interfere with the activity and structure of the protein (Rosano and 
Ceccarelli, 2014). 
In conclusion, TbbCATL, TcoCATL and TviCATL were recombinantly expressed, purified and 
subjected to an enzyme assay. TbbCATL showed no activity while TcoCATL and TviCATL 
were able to hydrolyse synthetic substrates and were inhibited by a class specific inhibitor. 
For future studies, TbbCATL would be recombinantly expressed using the methylotrophic 
yeast system P. pastoris without a tag, as done with TcoCATL and TviCATL. 
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Chapter 3  
Anti-TbbCATL antibody production in chickens and biopanning of 
single chain variable fragments from the Nkuku® phage library 
against recombinant TviCATL 
 
3.1 Introduction 
To achieve effective control of animal African trypanosomiasis, accurate diagnosis is 
essential. Diagnosis cannot rely on clinical symptoms alone as these are varied and may 
easily be mistaken for other diseases. Consequently, parasitological diagnostic techniques 
are often a necessity. However, these techniques are cumbersome and diagnosis is not 
immediate thus alternative diagnostic methods are sought (Büscher et al., 2017). Although 
research towards development of a reliable diagnostic test for AAT has been on-going for 
decades, not much progress has been made due to limited economical interest in veterinary 
diagnostics, inconsistencies in research priorities and financial resources.  
Improvement has been made with the development of molecular and serological diagnostic 
techniques such as polymerase chain reaction (PCR) detecting trypanosomal antigens and 
immunosorbent assays (ELISA). The latter is an indirect antibody detection test that has been 
used to detect T. congolense, T. vivax and T. brucei in infected animals. These ELISAs are 
sensitive, but not specific since the antigen used is usually a crude parasite lysate. Specific 
detection is dependent on the purity of the antigen therefore this technique lacks 
standardisation (Ezeani et al., 2008). In addition, antibodies are detectable even months after 
the disease is cured, therefore, these tests are not suitable follow ups. Card agglutination test 
for trypanosomes (CATT), an antibody based detected test, has been successfully used to 
detect T. b. gambiense infections but unsuccessful for T. b. rhodesiense infections (Büscher 
et al., 2013). Consequently, there is still a need for reliable and specific detection tools. 
Recently, a quick-format diagnostic test was developed for field diagnostics. The test is based 
on the recombinant cathepsin-B like cysteine protease from T. congolense (TcoCATB) and 
the tandem repeat protein (GM6) from T. vivax (TvGM6). Although this test showed high 
specificity, T. vivax infected animals gave a signal for both the TcoCATB and GM6 repeat. 
Additionally, the proteases were detected between two to four weeks of infection which is 
longer that the classical ELISA which detects them at one to two weeks after infection, 
therefore requires improvement (Boulangé et al., 2017). 
Antigen based ELISA tests such as sandwich ELISA are ideal for a diagnostic test as they 
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allow the detection of circulating parasite antigen, thereby diagnosing current infections rather 
than antibodies (Boulangé et al., 2017). Studies showed that trypanosomal cathepsin L-like 
cysteine proteases TcoCATL and TviCATL are released into the infected host bloodstream 
upon parasite lysis and is involved in pathogenesis during trypanosomal infections. 
Additionally, trypanotolerant cattle breeds challenged with TcoCATL, were reported to 
produce a prominent anti-TcoCATL IgG response which was not present in a susceptible cattle 
breed (Authié et al., 2001). Similarly, antibodies could be detected in the serum of cattle 
experimentally challenged with T. vivax and it was possible to discriminate infected and non-
infected sera in an ELISA based on recombinant TviCATL (Eyssen et al., 2018). Therefore, 
these proteases are promising targets in the development of diagnostic tools. Antigen based 
ELISAs require good antibodies with high specificity and sensitivity. 
In immunodiagnostic technologies which involve mammalian sera, chicken immunoglobulin 
(IgY) is considered the best antibody. This antibody does not cross react with mammalian IgG 
due to immunological differences, there is no cross-reactivity with Rh factor, is cost effective 
and easy to produce, making them desirable for research and diagnostics (Bird and Thorpe, 
2009). Furthermore, IgY is produced in the chicken egg yolk therefore does not require 
bleeding of animals, is produced rapidly in large amounts and are stable for long periods at 
4°C. Additionally, chickens can produce specific IgY against small amounts of antigens with 
poor immunogenicity (Amro et al., 2018). In the search of reliable serological diagnostic tools, 
it is imperative to find antibodies of highest specificity and their likelihood of misdiagnosis. 
Therefore, monoclonal, highly specific antibodies such as peptide antibodies and single chain 
variable domain fragments are preferred. 
Chicken immunoglobulin genes are also used to create a large library of antibody fragments 
such as single chain variable fragments (scFvs) and antigen binding fragments (Fabs) for 
phage display technology. The scFvs are displayed as fusion coat proteins on bacteriophages 
and recombinantly expressed in bacterial cells. They can recognise a variety of antigens and 
through several rounds of selection against a target antigen, mono-specific scFvs can be 
isolated, recombinantly produced and used for diagnostic and research purposes (Van 
Wyngaardt et al., 2004). 
This chapter reports the production and purification of chicken IgY against the recombinant T. 
b. brucei cathepsin L-like cysteine protease (TbbCATL). The cross-reactivity of anti-TbbCATL 
IgY, anti- N-terminal TcoCATL peptide and anti-TviCATL antibodies was evaluated by western 
blot and reported. Nkuku® phage library was used to pan for scFvs against recombinant 
TviCATL and the results are also reported in this chapter. 
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3.2 Materials and methods 
3.2.1 Materials 
Chicken IgY antibodies and ELISA: Freund’s complete and incomplete adjuvant were 
purchased from Sigma-Aldrich (USA). NUNC®-Immuno™ Maxisorb 96 well plates were 
purchased form ThermoFisher Scientific (USA), Bovine serum albumin (BSA) and 2,2-azino-
bis (3-ethylbenzothiazoline-6-sulphonic) acid (ABTS) were from Roche (Germany) 
Polyethylene glycol (PEG), Mr 6000, was purchased from Merck (Germany). Non-fat milk 
powder was purchased from VWR Life science (USA). 
Affinity purification: AminoLink® Coupling Resin was purchased from ThermoScientific 
(USA). 
Western blot analysis: Pre-stained marker was purchased from Separation Scientific (USA) 
and BioTrace™ nitrocellulose was from PALL Life Sciences (USA). 
Antibodies: Chicken anti- N-terminal TcoCATL peptide IgY and Chicken anti-TviCATL 
catalytic domain were previously produced in-house and rabbit anti-chicken IgY horseradish 
peroxidase (HRPO) antibodies were from Sigma-Aldrich (USA). 
Phage display technology: E. coli TG1 cells, Nkuku® phagemid library and M13KO7 wild 
type helper phages were obtained from Prof. Dion du Plessis and Dr Jeanni Fehrsen 
(Immunology Division, Onderstepoort Veterinary Institute, SA). NUNC® Immuno™ tubes and 
triethylamine were purchased from ThermoFisher Scientific (USA). Indolyl-β-D-
galactopyronoside (IPTG) was purchased from Fermentas (Vilnius, Lithuania). Ampicillin was 
purchased from Amresco (USA) and kanamycin from Life Technologies (UK). Sterile 0.22 µM 
filters and 96 well microtitre plates were purchased from PALL Life Sciences (USA) and Nest 
Bio Tech co (China) respectively. 
Antibodies for phage ELISA: Goat anti-mouse HRPO conjugate antibodies were purchased 
from Jackson ImmunoResearch Inc (USA), mouse anti-M13 antibodies were purchased from 
ThermoFisher Scientific (USA) and goat anti-rabbit HRPO conjugate was purchased from 
Jackson ImmunoResearch Inc (USA). 
3.2.2 Raising anti-TbbCATL antibodies in chickens 
Two chickens were immunised with purified GST-tagged TbbCATL by intramuscular injection 
in the breast muscle. The first immunisation was done with an emulsion of 50 µg of GST-
TbbCATL per chicken in 500 µl PBS with an equal volume of Freund’s complete adjuvant, 
followed by three booster immunisations prepared in the same manner with Freund’s 
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incomplete adjuvant every two weeks. Eggs were collected throughout the immunisation 
period. 
3.2.3 Isolation of chicken anti-TbbCATL IgY  
Antibodies were isolated from egg yolks as per Polson et al. (1985) and Goldring and Coetzer 
(2003). The egg yolks were separated from the albumin and rinsed with distilled water. The 
yolk volume was measured and mixed with double the volume of IgY buffer [100 mM Na-
phosphate buffer, pH 7.4 containing 0.02% (w/v) NaN3] in a beaker. To this mixture, 3.5% 
(w/v) polyethylene glycol (PEG) Mr 6000 was added and dissolved by gentle stirring, followed 
by centrifugation (4420 x g, RT, 30 min). The supernatant was filtered through cotton wool, 
the volume of the filtrate was measured and to that, 8.5% (w/v) PEG 6000 was added and 
dissolved by gentle stirring followed by centrifugation (4420 x g, RT, 10 min). The resulting 
pellet was dissolved in IgY buffer using a volume equal to the original egg yolk volume and 
12% (w/v) PEG 6000 dissolved and the precipitated IgY collected by centrifugation (12 000 x 
g, RT, 10 min). The resulting pellet was dissolved in 1/6 original egg yolk volume and the 
concentration determined: [IgY] = A280 ÷ 1.25 (extinction coefficient; Goldring and Coetzer, 
2003).  
3.2.4 Evaluation of anti-GST-TbbCATL IgY by enzyme linked immunosorbent assay 
(ELISA) 
The production of antibodies during the immunisation period was evaluated by enzyme-linked 
immunosorbent assay (ELISA). A 96 well NUNC-Immuno™ Maxisorp ELISA plate was coated 
with 150 µl of 1 µg/ml GST-tagged TbbCATL and incubated at 4ºC for 16 hours. The 
unoccupied spaces in the wells were blocked with 200 µl of 0.5% (w/v) BSA-PBS for 1 hour 
at 37ºC. The wells were washed with 3 x 300 µl PBS-Tween-20 [PBS with 0.1% (v/v) Tween-
20] using the Biotek ELx50 plate washer (BioTek® Instruments Inc., USA). The isolated anti-
TbbCATL IgY antibodies were added (100 µl of 100 µg/ml) to the wells and incubated at 37ºC 
for 2 hours followed by washing step and incubation with rabbit anti-chicken antibodies for 1 
hour. The wells were washed as previously followed by incubation with substrate solution 
[0.05% (w/v) ABTS. 0.005% (v/v) H2O2 in 150 mM citrate phosphate buffer, pH 5.5] for 1 hour. 
The absorbance readings were measured at 405 nm using the VERSA max Microplate Reader 
(Molecular Devices, USA).  
3.2.5 Affinity purification of anti-GST antibodies and evaluation by ELISA  
To purify anti-GST antibodies from anti-TbbCATL antibodies, glutathione (GST) was coupled 
to AminoLink® Coupling Resin according to the Thermo Scientific instruction manual. The resin 
(1 ml) was equilibrated with 6 ml of coupling buffer (0.1 M Na2PO4 buffer, pH 7.4, 0.1 M NaCl) 
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in a 10 ml BioRad column. The GST protein was diluted 4-fold in coupling buffer and added to 
the resin. Sodium cyanoborohydride solution (5 M NaCNBH3 in 1 M NaOH) (4 µl) was added 
to the column and incubated overnight at 4°C on an end-over-end rotator. The flow through 
was collected and the column washed with 4 ml coupling buffer. The unoccupied sites were 
blocked with 4 ml quenching buffer (1 M Tris-HCl, pH 7.4) followed by incubation with 
quenching buffer containing 40 µl 5 M NaCNBH3 at RT for 30 min on an end-over-end rotator. 
The column was washed with 10 ml of wash solution (1 M NaCl) and subsequently washed 
with 6 ml IgY buffer. 
Purified chicken anti-TbbCATL antibodies (isolated as per Section 3.2.3) were incubated with 
the GST affinity resin overnight at 4°C on an end-over-end-rotator. The incubation mixture 
was transferred into a 10 ml BioRad column and the flow through (anti-TbbCATL antibodies) 
collected. The column was washed with IgY buffer until an A280 of 0.02 was reached followed 
by elution with 20 ml of elution buffer (0.1 M glycine, pH 2.8). The elution fractions were 
collected, neutralised with 100 µl of quenching buffer (1 M Tris-HCl, pH 7.4) and absorbance 
was measured at A280. 
The purified anti-GST and anti-TbbCATL were evaluated in an ELISA as described in Section 
3.2.4 with the following amendments: the ELISA plate was coated with 150 µl of 1 µg/ml GST-
TbbCATL or GST. The isolated anti-TbbCATL IgY and anti-GST IgY antibodies were added 
to the respected antigens (100 µl of 100 µg/ml) to the wells before incubation at 37ºC. 
3.2.6 Evaluation of cross-reactivity by western blot between anti-TbbCATL, anti-peptide 
TcoCATL and anti-peptide TviCATL and their respective antigens 
Trypanosomal cysteine proteases TcoCATL, TviCATL and TbbCATL (20 µg) were separated 
by 12% reducing SDS-PAGE (Section 2.2.9) and a western blot was done as described in 
Section 2.2.10 with the following amendments: anti-N-terminal peptide TcoCATL, anti-
TviCATL and anti-TbbCATL IgY were the primary antibodies (10 µg/ml) and 1:10 000 of rabbit 
anti-chicken IgG-HRPO conjugate as the secondary antibody. The membranes were 
incubated in substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.1% (w/v) methanol, 
0.0015% (v/v) H2O2 in TBS] in the dark for 3 min and the image captured using the Syngene 
G: BOX (Vacutec, USA). 
3.2.7 Culturing of E. coli TG1s for phage display 
Glycerol stocks of E. coli TG1s cells were streaked onto TYE agar medium [1% tryptone, 0.5% 
yeast extract, 0.8% NaCl, 1.5% (w/v) agar] without antibiotic and incubated at 37ºC overnight. 
A single colony was inoculated into 5 ml of 2xYT medium [1.6% (w/v) tryptone, 1% (w/v) yeast 
extract, 0.5% (w/v) NaCl] and incubated at 37ºC with shaking (200 rpm) for 16 hours. Another 
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colony was incubated in 5 ml of 2xYT medium containing 5 µg/ml of ampicillin to serve as a 
control in which the absence of growth indicated that the cells were not infected. A total of 450 
ml of 2xYT medium was added to the 5 ml culture (1:100 dilution), grown until the OD600 was 
0.5 (log phase) and stored at 4ºC until further use (used within 1 week). 
3.2.8 Titering of M13KO7 helper phages 
A glycerol stock of M13KO7 helper phages was serially diluted from 10-2 to 10-13 in 2xYT 
medium, in sterile microfuge tubes. A total of 100 µl of each dilution was combined with 100 
µl of log phase E. coli TG1 cells and incubated at RT for 5 min. The mixture was combined 
with 4 ml of warm 0.7% (w/v) agar, plated onto pre-warmed 2xYT agar medium without 
antibiotic and left to solidify at RT followed by incubation at 37ºC for 16 hours. The titre of the 
stock was determined by calculating the plaque forming units (pfu) as follows: 
                 pfu/ml = Number of plaques x serial dilution 
                                           0.5 x 0.1 ml 
 
3.2.9 Culturing of M13KO7 helper phage 
A single plaque (from 10-10 dilution) was aseptically punched out of the agar plate using a 
sterile tip and inoculated into 4 ml of 2xYT medium containing 40 µl of the log phase E. coli 
TG1 cells and incubated at 37ºC with shaking (100 rpm) for 2 hours. After 2 hours, 2.2 ml of 
the culture was diluted into 400 ml of 2xYT medium in a 2 L baffled flask and incubated at 
37ºC with shaking (100 rpm) for 1 hour followed by addition of 50 mg/ml of kanamycin and 
incubated overnight (conditions were kept the same). The culture was centrifuged (10 800 x 
g, 4ºC, 15 min), 20% (w/v) PEG 6000 in 2.5 M NaCl was added to ¼ volume of supernatant 
(200 ml) and incubated on ice for 30 min followed by centrifugation (10 800 x g, 4ºC, 15 min 
and 2 000 x g, 4ºC, 2 min). The resulting pellet was resuspended in 6 ml of PBS and filter 
sterilised using a 0.22 µM filter. The phages were titred as previously (Section 3.2.8) and the 
concentration was determined by calculating the pfu/ml from the resulting plaques. 
3.2.10 Culturing of the Nkuku® phagemid library 
Using the phagemid glycerol stock, 250 µl was inoculated into 500 ml of 2xYT medium 
containing 100 µg/ml ampicillin and 2% (w/v) glucose in a 2 L baffled flask and incubated at 
37ºC with shaking (240 rpm) until an OD600 of 0.5 was reached. A total of 100 ml was removed 
from the culture and added to a 250 ml flask. The rest of the culture was incubated for a further 
3 hours and centrifuged (3 300 x g, 4ºC, 15 min). The resulting pellet was resuspended in 1 
ml 2xYT medium and stored in 15% (v/v) glycerol at -80ºC. 
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M13KO7 helper phage (8 x 109 pfu/ml) was added to the 100 ml culture and incubated at 37ºC, 
30 min, no shaking, followed by 30 min with shaking (100 rpm). The culture was centrifuged 
(3 300 x g, at 4ºC, 15 min) and the pellet was resuspended in 1 L 2xYT medium containing 
100 µg/ml ampicillin, and 25 µg/ml kanamycin in a 5 L flask. This was incubated at 30ºC with 
shaking (240 rpm) for 16 hours. The culture was centrifuged (3 300 x g, 4º, 15 min). To ¼ of 
the supernatant (200 ml), 20% (w/v) PEG 6000 in 2.5 M NaCl was added (in centrifuge tubes) 
and incubated on ice for 1 hour followed by centrifugation (3 300 x g, 4ºC, 15 min). The pellet 
was resuspended in 20 ml PBS and centrifuged (11 000 x g, 4ºC, 2 min). The resulting 
supernatant was filter-sterilised into a sterile tube using a 0.22 µM filter and stored at 4ºC for 
panning. 
3.2.11 Titering of the Nkuku® phagemid library 
A serial dilution of 10-2 to 10-7 from the Nkuku® phagemid library was done in 2xYT medium. 
The dilution was mixed with an equal volume of log phase E. coli TG1 cells (100 µl each) and 
incubated at RT for 5 min. The mixture was plated onto pre-warmed 2xYT agar medium 
containing 100 µg/ml ampicillin and 2% (w/v) glucose. To confirm that the E. coli TG1 cells 
were not infected, 100 µl of the culture was also plated and all the plates incubated at 30ºC 
overnight. The concentration of the Nkuku® phagemid library stock was determined by 
calculating the colony forming units (cfu/ml) as follows: 
                               cfu/ml = Number of colonies x dilution factor 
                                                           0.5 x 0.1 
 
3.2.12 Selection/ biopanning of scFvs against TviCATL 
Two immunotubes were coated with 3.5 ml of 100 µg/ml of TviCATL and incubated overnight 
at 4ºC. The tubes were washed three times with PBS to remove unbound protein. The 
unoccupied sites were blocked with 5 ml of 2% (w/v) non-fat milk-PBS and incubated at RT 
for 1 hour, two control tubes were simultaneously blocked with 2% (w/v) milk-PBS. The tubes 
were washed twice with PBS-Tween-20 and subsequently washed twice with PBS. A volume 
of 3.5 ml of milk-PBS was added to the protein coated tubes and 3.5 ml of 1 x 1013 Nkuku® 
phagemid in 2% (w/v) milk-PBS Tween-20 was added to the control tubes and incubated at 
37ºC for 30 min to eliminate milk binders from the library. The blocked Nkuku® phages were 
added to the protein coated immunotubes and incubated at RT for 30 min on an end-over-end 
rotator and 90 min standing to allow binding of high affinity phages to the immobilised protein. 
The tubes were washed 20 x with PBS-Tween-20, and 20 x with PBS to remove unbound 
phages. A volume of 1 ml of 100 mM triethylamine (made up just before use) was added to 
the tubes and incubated at RT for 10 min to elute the bound phages. The eluted phages were 
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transferred to a 2 ml microfuge tube containing 0.5 ml Tris-HCl buffer, pH 7.4. A volume of 1 
ml of the phages was added to a 50 ml falcon tube containing 5 ml of log phase E. coli TG1 
cells and incubated at 37ºC for 30 min. The cells were centrifuged (3300 x g, 4ºC, 10 min) and 
the resulting pellet was resuspended in 1 ml 2xYT medium w/o antibiotic. A volume of 333 µl 
was plated onto three 2xYT agar plates containing 100 µg/ml ampicillin and 2% (w/v) glucose 
and incubated overnight at 30ºC. 
The colonies were resuspended in 4 ml 2xYT medium of which 3 ml was stored in 15 % (v/v) 
glycerol at -80ºC. From the remaining 1 ml, 500 µl was added to 50 ml 2xYT medium 
containing 100 µg/ml ampicillin and 2% (w/v) glucose and incubated at 37ºC with shaking (200 
rpm) until the OD600 reached 0.5. A concentration of 8 x 109 pfu/ml of M13KO7 was added to 
5 ml of the culture and incubated at 37ºC for 30 min. The culture was centrifuged (3300 x g, 
4ºC, 10 min, slow deceleration). The pellet was resuspended in 25 ml 2xYT medium containing 
100 µg/ml ampicillin and 25 µg/ml kanamycin. The culture was incubated overnight at 30ºC 
with shaking (240 rpm). The culture was centrifuged (3300 x g, 4ºC, 20 min, slow deceleration). 
A volume of 5 ml 20% (w/v) PEG 6000 in 2.5 M NaCl was added to the supernatant and 
incubated on ice for 1.5 hours. This mixture was centrifuged (3300 x g, 4ºC, 30 min, slow 
deceleration), and the pellets were resuspended in 1 ml PBS and subsequently centrifuged 
(11 000 x g, 4ºC, 2 min). The phages were filter-sterilised with a 0.22 µM filter and either 0.5 
ml (unknown concentration) or 1 x 10 13 cfu/ml of the filtrates was used in the next round of 
panning to compare the two methods. 
3.2.13 Screening of phages by polyclonal ELISA 
Duplicate wells of a 96 well microtitre plate were coated with 100 µl of TviCATL (10 µg/ml and 
1 µg/ml) followed by incubation overnight at 4ºC. Control wells were coated with 3% (w/v) 
BSA-milk. The wells were blocked with 200 µl of 3% (w/v) PBS-milk and incubated at 37ºC for 
1 hour followed by incubation with 50 µl of 6% (w/v) BSA-PBS, containing 0.1% (v/v) Tween-
20 and 50 µl of the screened phages diluted in PBS (1:1). Nkuku® phages were used for the 
control wells and incubated at 37ºC for 2 hours. The wells were washed 3 x with 295 µl PBS- 
0.1% (v/v) Tween-20 followed by addition of 100 µl of 100 ng/ml anti-M13 antibody (1:8000 in 
3% (w/v) BSA-PBS) and incubated at 37ºC for 1 hour. The wells were washed as before and 
incubated with 100 µl of goat anti-mouse IgG conjugated to HPRO [1:1000 in 3% (w/v) BSA-
PBS] for 1 hour at 37ºC. The wells were washed as before and incubated with 100 µl ABTS 
[150 mM citrate-phosphate buffer, pH 5, 0.015% (w/v) ABTS, 0.005% (v/v) H2O2] at 37ºC for 
1 hour, and the absorbance measured at 405 nm using a VERSA max Microplate Reader 
(Molecular Devices, USA). 
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3.2.14 Screening of phages by monospecific ELISA 
Phages from panning round two and three were serially diluted (10-5 to 10-10) as described in 
Section 3.2.11. Single colonies were inoculated into 100 µl/well of 2xYT medium, in a sterile 
96 well microtitre culture plate and incubated at 30ºC for 16 hours with shaking (220 rpm). In 
a new plate, 2 µl of the overnight culture was inoculated in 150 µl 2xYT medium containing 
100 µg/ml ampicillin and 2% (w/v) glucose and incubated at 37ºC for 2.5 hours with shaking 
(220 rpm). The remaining culture was stored in 15% (v/v) glycerol at -80ºC (this was referred 
to as the master plate). At the end of 2.5 hours, 50 µl/well of 2 x 109 M13KO7 helper phages 
(diluted in 2xYT medium) was added and incubated at 37ºC for 30 min with no agitation. The 
culture was centrifuged (600 x g, 4ºC, 10 min) and the pellet was aseptically resuspended in 
150 µl/well 2xYT medium containing 100 µg/ml ampicillin, 25 µg/ml glucose and incubated 
overnight at 30ºC with shaking (220 rpm). A non-sterile 96 well microtitre plate was coated 
with 100 µl of 10 µg/ml TviCATL and incubated at 4ºC for 16 hours. 
The unoccupied sites of antigen coated plate were blocked with 3% (w/v) BSA-PBS (200 
µl/well) and incubated at 37ºC for 1 hour. The overnight culture was centrifuged (600 x g, 4ºC, 
10 min) and 50 µl of the supernatant was added to the blocked plate as well as 50 µl 6% (w/v) 
BSA-PBS containing 0.1% (v/v) Tween-20 and incubated at 37ºC for 2 hours. The plate was 
washed three times with 300 µl PBS-Tween-20 using the Biotek ELx50 plate washer followed 
by addition of 100 µl/well of mouse anti-M13 antibody (1:8000 in 3% (w/v) BSA-PBS) and 
incubation at 37ºC for 1 hour. The plate was washed as before and 100 µl/well of goat anti-
mouse HRPO (1:1000 in 3% (w/v) BSA-PBS) added and incubated at 37ºC for 1 hour. The 
plate was washed as before and 100 µl of ABTS [150 mM citrate-phosphate buffer, pH 5, 
0.015% (w/v) ABTS, 0.005% (v/v) H2O2] was added and incubated at 37ºC for 1 hour. The 
absorbance was measured at 405 nm using the VERSA max Microplate Reader (Molecular 
Devices, USA). 
3.3 Results 
3.3.1 Evaluation of anti-GST-TbbCATL IgY by ELISA 
The IgY isolated from one egg from each chicken collected each week of the immunisation 
period, was incubated in a GST-TbbCATL coated ELISA plate. Antibody production in both 
chickens increased over time (Fig 3.1). Chicken 1 showed a peak of IgY production at 3 weeks 
and a slight decrease over weeks 5-7, before reaching another sustained peak at weeks 8-
16. Chicken 2 showed a gradual increase in antibody production especially beyond 15 weeks. 
The A405 readings were generally quite low for both chickens apart form weeks 15-16 for 
chicken 2 (Fig. 3.1). 
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Figure 3.1: Evaluation of chicken anti-TbbCATL IgY production by ELISA. A 96 well plate was 
coated with 1 µg/ml of TbbCATL. The primary antibody was IgY isolated from single eggs from weeks 
0-16 at 100 µg/ml and the secondary antibody was rabbit anti-chicken IgY antibodies conjugated to 
HRPO, the substrate was ABTS·H2O2 and the absorbance was measured at 405 nm after 1 hour and 
readings were corrected by subtracting the negative control. Arrows are an indication of immunisations. 
 
3.3.2 Removal of anti-GST antibodies using a GST affinity column 
The chickens were immunised with TbbCATL containing a GST tag, therefore, to separate 
anti-GST antibodies from anti-TbbCATL antibodies the total IgY was affinity purified using a 
GST affinity column. The A280 readings of the unbound fraction showed elution of the anti-
TbbCATL antibodies over a 50 ml volume while A280 readings of anti-GST antibodies showed 
that the antibodies were eluted from the column between 50 ml and 56 ml (Fig. 3.2). 
                 
Figure 3.2: Elution profile of anti-GST antibodies from GST affinity column. IgY isolated from 
chickens 1 and 2 at weeks 8-11 and weeks 14-16 respectively was used to affinity purify anti-GST 
antibodies on a GST affinity column. The bound anti-GST antibodies were eluted with 0.1 M glycine-
HCl, pH 2.8 and A280 of the fractions collected measured. The inset shows the A280 readings of the 
unbound fraction which contains the anti-TbbCATL IgY antibodies from chickens 1 and 2. 
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3.3.3 Detection of GST-TbbCATL by anti-TbbCATL antibodies in an ELISA 
Following separation from anti-GST antibodies, the detection of GST-TbbCATL by the anti-
TbbCATL antibodies was evaluated in an ELISA. Crude IgY (before affinity purification) and 
pre-immune antibodies were used as controls. Antibodies from chickens 1 and 2 were able to 
detect GST-TbbCATL with anti-TbbCATL IgY showing higher absorbance values compared 
to anti-GST IgY (Fig. 3.3) which means that there were more antibodies against TbbCATL 
compared to the GST tag. The detection of GST by affinity purified anti-GST IgY antibodies 
was also evaluated in an ELISA (Fig. 3.4). The affinity purified anti-GST antibodies from 
chickens 1 and 2 were able to detect GST, showing the highest absorbance readings followed 
by crude IgY (before affinity purification), while the anti-TbbCATL antibodies remaining after 
removal of anti-GST antibody showed negligible detection of GST (similar to non-immune 
control antibodies). 
 
Figure 3.3: Detection of TbbCATL by anti-TbbCATL and anti-GST antibodies in an ELISA. 
Microtitre plates (96 well) were coated with 1 µg/ml of TbbCATL and incubated with increasing 
concentrations of anti-TbbCATL IgY and anti-GST IgY antibodies (0.5 µg/ml-100 µg/ml) collected after 
affinity purification. The secondary antibody was rabbit anti-chicken IgY IgG-HRPO conjugate and 
substrate ABTS·H2O2. Pre-immune and crude IgY antibodies were used as controls and absorbance 
was measured at 405 nm. Panels C and D are an enlargement of A and B respectively, showing the 
absorbance values for IgY concentrations 0.5-10 µg/ml for.  
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Figure 3.4: Detection of GST by affinity purified anti-GST and anti-TbbCATL IgY antibodies in an 
ELISA. Microtitre plates were coated with 1 µg/ml of GST and incubated with increasing concentration 
of affinity purified chicken anti-GST IgY and anti-TbbCATL IgY antibodies (0.5-100 µg/ml). The 
secondary antibody was rabbit anti-chicken IgG-HRPO conjugate and substrate was ABTS·H2O2. Pre-
immune and crude IgY antibodies were used as controls and A405 was measured. The insets show the 
absorbance values for IgY concentrations 0.5-10 µg/m 
 
3.3.4 Evaluation of cross-reactivity by western blot of anti-TbbCATL, anti-TviCATL and 
anti-peptide TcoCATL antibodies and the respective antigens.  
To evaluate the possibility of cross-reactivity of the antibodies, GST-TbbCATL, TviCATL and 
TcoCATL, separated by reducing SDS-PAGE and transferred to a nitrocellulose membrane, 
were allowed to interact with anti-TbbCATL, anti-TviCATL and anti-TcoCATL N-terminal 
peptide IgY in a western blot (Fig. 3.5). Anti-TcoCATL N-terminal peptide IgY detected the 
TcoCATL protein band at 30 kDa, TbbCATL at 61 kDa and did not detect TviCATL (Fig. 3.5, 
panel A). Anti-TviCATL IgY antibodies detected TviCATL, with a prominent band at 29 kDa, 
as well as TbbCATL at 61 kDa (Fig. 3.5, panel B). Anti-TbbCATL IgY antibodies only detected 
TbbCATL at 61 kDa (Fig.3.5, panel C).  
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Figure 3.5: Evaluation of cross-reactivity by western blot between anti-peptide TcoCATL, anti-
TviCATL and anti-TbbCATL antibodies and their respective antigens. TbbCATL, TviCATL and 
TcoCATL were separated on a 12% reducing SDS-PAGE gel and transferred onto a nitrocellulose 
membrane. Unoccupied sites were blocked with 5% (w/v) non-fat milk and incubated with 20 µg/ml of 
A, anti-peptide TcoCATL, B, anti-TviCATL and C, anti-TbbCATL IgY. Rabbit-anti-chicken IgY-HRPO 
conjugate was the secondary antibody and 1-chloronaphthol·H2O2 was the substrate.  
 
A sequence alignment was done for the cathepsin L-like cysteine proteases from T. cruzi, T. 
vivax, T. b. brucei and T. congolense using Clustal Omega (Chapter 2, Fig 2.1). The anti- 
TcoCATL peptide antibodies used in the western blot were against the N-terminal sequence 
highlighted in blue (APEAVDWRKKGAVTPVKDQGQC). The sequence identity showed that 
TbbCATL shares 70% identity with TcoCATL and 62% identity with TviCATL (Table 3.1), thus 
explaining the cross-reactivity observed in the western blot. 
 
Table 3.1 Sequence identities of trypanosomal cathepsin L-like cysteine proteases 
  Sequence identities of CATL   
Sequence TcrCATL TviCATL TbbCATL TcoCATL 
TcrCATL 100% 62% 57% 55% 
TviCATL 62% 100% 64% 62% 
TbbCATL 57% 64% 100% 70% 
TcoCATL 55% 62% 70% 100% 
3.3.5 Selection/ panning of scFvs from Nkuku® phage display library recognising 
TviCATL 
To select for scFvs with high affinity and specificity, the Nkuku® library was panned for 
TviCATL binders. An unknown concentration of phages was compared to 1x 1013 cfu/ml for 
each panning round to compare the specificity of the scFvs and reproducibility of the results 
obtained. The scFvs were evaluated by ELISA (Fig. 3.6). At 1 x 1010 cfu/ml, an increase in 
signal was observed from pan 0 to pan 1 which is an indication of enrichment of specific scFvs 
(Fig. 3.6, panel A). However, this decreased in pan 2, followed by an increase in pan 3 and 
another decrease in pan 4 (Fig. 3.6, panel A). In the parallel experiment using an unknown 
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concentration of phages, enrichment is observed in pans 2 and 3, before a decrease in signal 
is observed in pan 4 (Fig. 3.6, panel B). 
 
 
Figure 3.6: Screening of scFvs by polyclonal ELISA. The 96 well plates were coated with 10 µg/ml 
and 1 µg/ml TviCATL and incubated with scFvs isolated from each round of panning. Binders were 
detected with 1:8000 mouse anti-M13 antibody (primary) and 1:1000 goat anti-mouse-HRPO followed 
by ABTS·H2O2 substrate incubation and measuring the absorbance at 405 nm. A, 1 x1013 cfu/ml phage 
concentration was used for each panning round. B, Unknown phage concentration used in each 
panning round. 
 
To select for clones with the highest specificity for TviCATL, the phages with the highest 
signals in polyclonal ELISA (Fig. 3.7) were used for screening of monospecific scFvs by 
ELISA. For the colonies from panning done with 1 x 1010 cfu/ml (Fig. 3.7, panel A), A1, A3, 
A11, A12 and B9 (●) gave strong signals. When the phage concentration was unknown, a 
strong signal was observed in H1 (which was also the strongest signal among the two 
experiments) and G3 (Fig. 3.7, panel B). 
 
Figure 3.7: Screening of scFvs from pan 3 by monospecific ELISA. A total of 48 single colonies, 
infected with phages from pan 3, were cultured in a 96 well microtitre plate. The phages were rescued, 
isolated and allowed to interact with 10 µg/ml TviCATL. Mouse anti-M13 antibody (1:8000), goat anti-
mouse HRPO conjugate antibody (1:10 000) and ATBS·H2O2 substrate were used. The absorbance 
was measures at 405 nm. A, 1 x1013 cfu/ml phage concentration used for each panning round.  B, 
Unknown phage concentration used during panning. 
69 
 
3.4 Discussion 
Antibody detection tests for AAT diagnosis are often based on the whole parasite lysate or 
host antibodies as a target (Torres et al., 2018). This poses a challenge as the lysate 
preparation methods are not standardised and propagation techniques (especially for T. vivax) 
are often difficult. Additionally, species specific diagnosis of AAT has been difficult due to the 
high level of homology between the causative species (Boulangé et al., 2017). 
Lysosomal cysteine proteases from T. b. brucei, T. congolense and T. vivax are the major 
antigens in cattle infections. They are present throughout the life cycle of the parasite and 
highly immunogenic. There is also a correlation between cysteine protease-specific IgG 
response and trypanotolerance, hence the high interest in these proteases (Authié et al., 
2001). The results presented in this chapter reported the analysis of antibodies against 
recombinant TbbCATL, TcoCATL and TviCATL as potential diagnostic tools. 
There are various ways to produce antibodies with different specificities. In previous studies, 
anti-peptide antibodies were produced against free and carrier-conjugated peptides 
corresponding to a discrete amino acid sequence of TbbCATL(Troeberg et al., 1997) . Anti-
peptide antibodies were raised in chickens and rabbits and the two forms of the peptide were 
found to be equally immunogenic in both species. High antibody titres were observed three 
weeks after initial immunisation with the conjugated peptide and after eight weeks with the 
free peptide. Antibodies against trypanosomal cysteine proteases have also been detected in 
trypanosome infected cattle (Authié et al., 2001; Eyssen et al., 2018). Anti-TcoCATL 
antibodies have also been raised in rabbits where it was found that the use of Freund’s 
adjuvant elicited a strong antibody response (Huson et al., 2009). 
In the present study, antibodies against recombinantly expressed GST-TbbCATL were 
produced in chickens and together with previously produced anti-TcoCATL N-terminal peptide 
and anti-TviCATL antibodies, were evaluated by western blot to determine possible cross-
reactivity with the respective antigens. The results showed the presence of cross-reactivity of 
the anti-TcoCATL N-terminal peptide and anti-TviCATL antibodies with TbbCATL, even 
though anti-peptide antibodies are known to have a specificity similar to that of monoclonal 
antibodies as they are directed to a specific peptide in a protein (Fig. 2.1). The observed cross-
reactivity was expected since TcoCATL and TbbCATL share 70% sequence identity (Table 
3.1). The reactivity observed between anti-TviCATL antibodies and TbbCATL is also an 
indication of sequence identity between these proteases. However, despite the broad 
specificity of polyclonal antibodies and high percentage identity between the three proteases, 
the anti-TbbCATL antibodies produced here were specific for TbbCATL and did not cross-
react with either TcoCATL or TviCATL which makes them a promising tool for the specific 
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detection of T. b. brucei infections. 
Due to the challenges that were encountered with purification of the recombinantly expressed 
GST-TbbCATL fusion protein, the fusion protein was used for antibody production and the 
anti-GST antibodies were removed from the anti-TbbCATL antibody preparation. However, it 
may be preferred to affinity purify the antibodies using TbbCATL (after the removal of the 
fusion protein tag) rather than GST to ensure that none of the anti-GST antibodies are left in 
the antibody sample. Furthermore, further experiments will require the removal of the GST tag 
because it seems to interfere with applications of the protease such as activity assays as 
mentioned in Chapter 2 (Section 2.4). This would also ensure that the antibodies produced 
are only against the protein of interest and not the fusion tag. 
Antibodies derived from phage display have been used for diagnostic purposes. The main 
challenge with commercial antibodies is that they have poor specificity, cannot recognise the 
target antigen or are not available. Phage display has been used for biopanning of human 
recombinant scFvs against a T. cruzi P2β ribosomal protein (Grippo et al., 2011) and 
Plasmodium falciparum surface protein Pfs25, P. falciparum chitin 1 and P. falciparum 
circumsporozoite protein (Isaacs et al., 2011). 
In the present study, the Nkuku® phagemid library was used to select for scFvs with high affinity 
and specificity for TviCATL. The difficulties to obtain sufficient amounts of recombinant 
TbbCATL informed the decision to work with TviCATL as a model antigen to learn how the 
phage display technology and optimise the system. The Nkuku® phagemid library has a highly 
diverse repertoire which produces antibody fragments that can recognise haptens, proteins 
and viruses (Van Wyngaardt et al., 2004). The rescued phages were enriched after the third 
round of panning. Additionally, the use of a constant concentration of phages (1 x1013 cfu/ml) 
was compared to an unknown concentration (0.5 ml) during biopanning. When 0.5 ml of 
rescued phages was used, only two clones showed a strong signal when evaluated by 
monospecific ELISA. Even though more clones showed a stronger signal when 1 x 1013 cfu/ml 
was used, it cannot be concluded from this experiment alone which of the two methods is best 
to use. Expression and sequence analysis of these scFv would be required for their potential 
use as diagnostic tools. 
The antibodies and scFvs produced in this study present a promising start for the development 
of a serological diagnostic test for AAT. The ability of the anti-TbbCATL IgY antibodies to 
discriminate TcoCATL and TviCATL makes them ideal capture antibodies for an antigen-
based ELISA such as a sandwich ELISA (Fig. 3.8). For species-specific antigen detection, the 
capture antibodies need to recognise distinct epitopes on the target antigen. Capture or 
detection antibodies may also be substituted with scFvs. The successful application of 
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nanobodies, which are variable domains of camel antibody heavy chains, as capture 
antibodies in a lateral flow assay for the specific detection of T. congolense has been reported 
(Torres et al., 2018). It is suggested that a TbbCATL-detection ELISA could have the format 
illustrated in Fig. 3.8. The capture antibody could be chicken anti-TbbCATL IgY, that would 
recognise the target antigen, TbbCATL, in infected cattle serum samples. An E-tagged scFv 
specific for TbbCATL selected to recognise a different epitope on TbbCATL would be detected 
with a HRPO-labelled rabbit anti-E-tag antibody followed by an appropriate 
chromogen/substrate system (Ahmad et al., 2012). 
                                            
Figure 3.8: Schematic representation of a sandwich ELISA. 
 
The results presented in this chapter showed that the anti-TbbCATL antibodies produced in 
chickens did not cross-react with TcoCATL and TviCATL and are therefore promising tools for 
specific diagnosis of T. b. brucei infections. For future studies, TbbCATL without a tag would 
be used to produce antibodies. By using TviCATL as antigen, binders were identified in the 
Nkuku® scFv phage display library and this can be expanded to the development of TbbCATL-
specific scFvs for use in diagnostic assays for T. b. brucei infection. 
Chapter 4 
General discussion 
African trypanosomes are the causative agents for human African trypanosomiasis (HAT) and 
animal African trypanosomiasis (AAT) in sub-Saharan Africa. The human infective species are 
Trypanosoma gambiense and T. rhodesiense and the animal infective species are T. b. brucei, 
T. congolense and T. vivax (Muhanguzi et al., 2017). These trypanosome parasites are 
transmitted by the tsetse fly (Glossina spp.), except for T. vivax that is also mechanically 
transmitted by other haematophagous flies such as horseflies (Tabanus spp.) and stable flies 
(Stomoxys spp.) and is consequently also found in parts of Asia and South America (Giordani 
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et al., 2016). The parasite escapes the host’s immune response by switching genes coding 
for the variable surface glycoproteins, resulting in new variable antigen types. This has made 
it unlikely to develop a vaccine. Due to the negative impact this disease has on the economy, 
many research studies are aimed at controlling and treating trypanosomiasis. 
Chemotherapy and chemophylaxis are the main control measures in place for 
trypanosomiasis, however, the use of these drugs is limited by the emergence of drug 
resistance and unwanted toxicity (Giordani et al., 2016). The drugs used for HAT treatment 
depend on the causative species and stage of the disease. Suramin and pentamidine are used 
to treat the first stage of HAT. Suramin is effective against both HAT causing species while 
pentamidine is effective against gambiense HAT. Melarsoprol, nifurtimox and eflornithine are 
used to treat the second stage of HAT. These drugs have been associated with adverse side 
effects and the latter is effective against T. b. gambiense and not T. b. rhodesiense (Caffrey 
et al., 2001; Büscher et al., 2017). 
The commonly used curative drug for AAT is diminazene aceturate and is used to treat 
infections in cattle, sheep and goats. Other drugs include isometamidine chloride, 
melarsomine dihydrochloride, suramin and quinapyramine which are used as prophylactic 
drugs. Correct administration and supportive measures are required for satisfactory treatment 
of ATT (Melaku and Birasa, 2013). The drugs are often administered by farmers themselves 
without any supervision and treatment is sometimes used without proper diagnosis (Giordani 
et al., 2016). Due to the decrease in the development of new drugs, there is a compelling need 
to preserve the existing drugs.   
Effective control and prevention of trypanosomiasis depend on the availability of sensitive and 
accurate diagnostic tools. Rapid diagnostic tests are preferred since treatment can be 
administered as early as possible (Torres et al., 2018). Furthermore, rapid diagnostic tests are 
required to comply with the “ASSURED” (Affordable, Sensitive, Specific, User-friendly, Rapid 
and robust, Equipment free and Deliverable to end-users) criteria. Such tests have been 
developed for HAT diagnosis i.e. the HAT Sero-K-SeT (Coris BioConcept, Gembloux, 
Belgium) and the SD Bioline HAT 1.0 (Standard Diagnostics, Yongin, South Korea). However, 
these only detect T. b. gambiense infections and no applicable test exists for T. b. rhodesiense 
infections (Büscher et al., 2017). 
DNA-based assays such as PCR and LAMP are reliable, sensitive and specific for AAT 
diagnosis, however, are not applicable in the field as they require sophisticated equipment 
and experienced personnel. Alternatively, diagnosis of trypanosomiasis is often based on the 
whole parasite lysate antigens (derived from experimental rodent infection) to detect host 
antibodies against the parasite. This approach presents its own problems because a low 
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antibody response may result in false negative results. Sera may also contain antibodies 
against other co-infecting parasites such as Theileria or Babesia that may cross-react with the 
trypanosome lysate antigens. Antibodies are also detectable for weeks after treatment 
therefore it cannot be determined whether an infection is current (Torres et al., 2018). This 
can be overcome using antigen-based tests. Recombinant antigen-based tests allow the 
detection of current infections as well species-specific diagnosis (Bossard et al., 2010). Among 
the non-variant molecules, cysteine proteases have been identified and validated as potential 
diagnostic targets (Boulangé et al., 2017; Eyssen et al., 2018). 
Cysteine proteases are members of the papain-like family and have been reported in several 
parasites including Plasmodium spp., Trypanosoma spp. and Leishmania spp. (Melaku and 
Birasa, 2013). In African trypanosomes, cysteine proteases are expressed throughout the life 
cycle and are essential for the survival of the parasite (Mbawa et al., 1992). The cathepsin L-
like proteases from T. congolense, TcoCATL, and TviCATL from T. vivax are released into the 
bloodstream of the infected host upon parasite lysis (Eyssen et al., 2018). Additionally, 
trypanotolerant cattle were found to produce a high antibody response against TcoCATL 
compared to susceptible species (Authié et al., 2001). Anti-TviCATL antibodies were also 
detected in the blood serum of TviCATL infected cattle and not in the non-infected cattle 
(Eyssen et al., 2018) making these proteases promising targets in the development of 
diagnostic tools. 
The overall aim of this study was to produce anti-TbbCATL antibodies which can be used for 
specific diagnosis of T. b. brucei infections in antigen-detection immuno-assays. The protease 
TbbCATL was recombinantly expressed in E. coli for the first time to avoid potential intellectual 
property restrictions associated with the Pichia pastoris expression system based on the 
strong AOX1 promoter (Ahmad et al., 2014). Since E. coli is quick and inexpensive to culture 
and high protein yields can be obtained at small scale due to the strong T7 promoter (Bill, 
2014), recombinant expression of TbbCATL was explored in E. coli. 
The TbbCATL gene was identified (Mottram et al., 1989) and amplified from the genomic DNA 
in a PCR reaction. The DNA fragment was ligated into PTZ57R/T TA cloning vector with no 
significant mutations. The gene was sub-cloned into pET32a, pET28a and pGEX-4T 
expression vectors and transformed into E. coli BL21 (DE3) cells. The homologue from T. 
cruzi has been expressed in E. coli (Eakin et al., 1993) but previous attempts to express 
TcoCATL in a bacterial system resulted in an incorrectly folded and inactive enzyme 
(Boulangé et al., 2001). However, since the aim of this project was to produce an antigen for 
antibody production, catalytic activity of TbbCATL was not a requirement. An advantage of 
using a pET vector such as pET28a, is that the recombinant protein contains a small His-tag 
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that is useful for purification. A large fusion protein may be immunogenic and hence needs to 
be removed after purification before antibody production. A study by Lanfranco et al. (2008) 
reported the expression of the truncated form of a cathepsin B-like cysteine protease from 
Leishmania braziliensis in E. coli in a pQE80L expression vector. Although human cathepsin 
B has been expressed in E. coli using a pET vector (Chan and Fong, 1988), there was no 
TbbCATL expression in either pET28a or pET32a in the present study. This may explain why 
there are no reports on successful expression of the trypanosomal cathepsin L-like cysteine 
proteases in E. coli using the pET vectors. However, TbbCATL was expressed in soluble form 
using the pGEX-4T vector (which adds a 26 kDa GST tag) and purified using a glutathione-
agarose resin. 
In a previous study, the methylotrophic yeast P. pastoris was investigated as an expression 
system and reported suitable for the expression of TcoCATL (Boulangé et al., 2011). Since 
then, recombinant cathepsin B-like and cathepsin L-like cysteine proteases from T. b. 
rhodesiense as well as TviCATL have been expressed in P. pastoris (Mendoza-Palomares et 
al., 2008; Steverding et al., 2012; Eyssen et al., 2018). In the present study, TcoCATL and 
TviCATL were recombinantly expressed in P. pastoris and purified by three-phase partitioning 
(TPP) followed by molecular exclusion chromatography (MEC). Both TcoCATL and TviCATL 
hydrolysed the synthetic substrate Z-Phe-Arg-AMC and were inhibited by the class specific 
inhibitor E-64. Although E. coli remains the most common host for recombinant expression in 
both commercial and research laboratories (Rosano and Ceccarelli, 2014), it has been shown 
that P. pastoris has gained recognition for its ability to produce more challenging protein 
targets. Other advantages of using yeast include high protein yields, secretion of protein into 
the culture medium and post translation modification (Bill, 2014). A study by Shen et al. (2016) 
reported the use a non-methanol carbon source, dihydroacetone, to overcome the limitations 
associated with methanol. The methanol induced promoter AOX1 has also been used for 
recombinant expression of a phytase reporter protein without the addition of methanol but by 
co-expression with a positively acting transcription factor Pmlp (Ahmad et al., 2014). While 
there is no certainty which host will produce functional yields, it has been suggested that yeast 
be considered in the early strategies of recombinant expression (Bill, 2014). Therefore, 
expression of TbbCATL in P. pastoris should be considered for future studies. 
In a previous study, Z-Phe-Arg-AMC was found to be an appropriate substrate for the native 
TbbCATL (Troeberg et al., 1996). Failure to cleave the substrate observed in the present study 
was accounted for by the presence of the GST tag. All attempts to cleave off the tag were 
unsuccessful therefore further studies were conducted with the GST-tagged TbbCATL. It has 
been reported that the GST tag does interfere with the activity and the structure of the protein 
therefore like other fusion tags, should be removed prior to downstream applications of the 
75 
 
protein (Rosano and Ceccarelli, 2014). 
As indicated before, antigen-based immuno-detection has advantages over antibody-based 
techniques for accurate diagnosis of AAT but relies on good antibodies. In the present study 
polyclonal antibodies were produced against TbbCATL and producing scFvs specific for 
trypanosomal cathepsin L-like proteases using phage display technology was explored using 
TviCATL for biopanning. In a sandwich ELISA, these capturing antibodies would interact with 
the antigen prior to the detection antibodies, therefore must be able to recognise specific 
epitopes on the target antigen and be able to outcompete the host’s antibodies (Torres et al., 
2018). In a study by Troeberg et al. (1997), antibodies were produced in rabbits and chickens 
against the native TbbCATL and also against peptides corresponding to discrete sequences 
of TbbCATL. In the present study, anti-TbbCATL antibodies were produced in chickens 
because they are easy to handle and do not require bleeding since the antibodies are 
packaged in the egg yolk. Additionally, chicken IgY has been reported to be the best antibody 
for research diagnostics because it does not cross-react with mammalian IgG due to 
immunological differences and is easy to produce in a cost effective manner (Bird and Thorpe, 
2009). In this study, anti-TbbCATL IgY was able to discriminate TcoCATL and TviCATL while 
anti-N-terminal peptide TcoCATL and anti-TviCATL cross-reacted with TbbCATL in a western 
blot. This was an interesting observation because the TbbCATL antibodies were produced 
against the whole protein, which means they are more likely to recognise multiple epitopes 
leading to cross-reactivity with TcoCATL and TviCATL as these proteases share similarities 
in their sequences (Table 3.1). On the other hand, the anti-peptide TcoCATL antibodies are 
against a single specific epitope and therefore less likely to cross-react. 
The cross-reactivity observed with TbbCATL indicated a challenge with specific diagnosis, 
especially in cases where mixed infections are present. Anti-peptide antibodies are more 
specific because they are directed against a specific epitope on the protein (Troeberg et al., 
1997). In this study, anti-peptide TcoCATL antibodies did not cross-react with TviCATL and 
anti-TviCATL antibodies did not cross-react with TcoCATL which is promising for AAT 
diagnosis. Further cross-reactivity studies are required where anti-peptide TbbCATL 
antibodies will be used. However, the polyclonal antibodies produced in this study are 
promising tools for the development of an ELISA based serological diagnostic test. The 
antibody specificity observed in this study indicated the possibility of a specific antibody-
antigen complex which can be translated into a lateral flow assay (LFA). 
Lateral flow assays provide a combination of biorecognition and chromatography in different 
formats such as sandwich ELISA. Briefly, the antibody is immobilised on a conjugate pad and 
a sample containing the antigen is applied to the pad and moves to other parts of the strip. 
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Upon migration, the antigen is captured at the conjugate pad, forming a specific antigen-
antibody complex which is detected by another labelled antibody at the test line, forming a 
sandwich (Fig. 3.8). The excess labelled antibody is captured at the control line (Ngom et al., 
2010). The LFA has been described in the detection of T. vivax infections in cattle, based on 
immunodominant two invariant surface glycoproteins. The IgG from infected calves were used 
as capture antigens and were able to distinguish between infected and non-infected cattle, as 
well as T. vivax and T. congolense infected sera (Fleming et al., 2016). This technique has 
also been reported for T. b. gambiense infections in humans, where IgG was directed against 
ISG65 (Sullivan et al., 2013). 
Recombinant antibodies derived from phage display technology have been applied in different 
diagnostic platforms such as lateral flow strips and bead-based assays. The main advantage 
of using recombinant antibodies is that they can be modified (Bahara et al., 2013), for example, 
the display of antibody fragments with binding activity on the surface of bacteriophages (Kuhn 
et al., 2016). The use of scFvs derived from monoclonal antibodies for the diagnosis of human 
immunodeficiency virus (HIV) has been described (Lilley et al., 1994). Single chain variable 
fragments have also been used to control malaria infections by binding and neutralising 
plasmodium merozoite surface protein 1 (MSP1) and the apical membrane protein 1 (AMA1). 
Additionally, a peptide ligand derived from phage display was found to inhibit the invasion of 
P. falciparum into human erythrocytes (Li et al., 2002; Goulart et al., 2017). The use of scFvs 
from a buffalo serum derived library to detect a Schistosoma japonicum antigen in an ELISA 
was also reported (Hosking et al., 2015). 
In this study, scFvs specific for TviCATL were selected from a Nkuku® phage display library. 
The phages were enriched after the third round of panning and a total of seven clones gave 
high signals when analysed by monospecific ELISA. Further work to express and purify these 
scFvs needs to be done. Histidine tagged scFvs with strong affinity for target proteins can be 
selected and amplified, followed by purification using immobilised metal affinity 
chromatography. The scFvs are primarily screened by SDS-PAGE, western blot or ELISA for 
their ability to recognise the target antigen. Further applications of the scFvs would require 
expression in E. coli and a sequence analysis (Goulart et al., 2017). 
In conclusion, TbbCATL was recombinantly expressed in E. coli and used as an immunogen 
for antibody production in chickens. The anti-TbbCATL antibodies produced were able to 
discriminate TcoCATL and TviCATL in a western blot and together with scFvs produced using 
the methodology optimised here are promising leads for designing species-specific diagnostic 
tests for animal African trypanosomiasis.  
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